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Abstract
Venous thrombosis is a serious health problem affecting 1 in 1000 individuals
annually.

Until recently the pathogenic factors underlying thrombosis were

associated with genetic defects in protein C, protein S and antithrombin III.
However these were recognised in fewer than 5-10% of thrombotic patients.

A

breakthrough was made with the discovery of activated protein C resistance (APCr)
which is associated in 90% of cases v/herein a G-->A transition in the factor V gene
results in an abnormal molecule, Factor V Leiden. APCr is a major risk factor for
thrombosis being present in 20-60% of thrombotic patients. Recently a G-^A new
mutation at the 3’-untranslated region (UTR) of the prothrombin gene was
described.

This mutation increases the level of prothrombin in blood by a

mechanism(s) which remain(s) to be defined. Furtherm.ore this mutation is thought
to be linked to thrombosis since it is present in 6% of thrombotic cases.

This work is divided between three areas. The first part of this study examined 40
thrombotic patients and 40 normal

individuals

coagulation-based assays for detection of APCr.

using two commonly used
Comparisons of analytical

specificity and sensitivity were made as a means of critically assessing the kits
performance. Genotype assignments for factor V were also determined using sitedirected mutagenesis (SDM)-polymerase chain reaction (PCR).

!n the second part of this study a ‘single-tube’ amplification refractory mutation
(ARMS) detection strategy for factor V Leiden and the prothrombin variant was
developed.

Essentially these strategies used fluorescent-based differentially-

labelled primers to simultaneously amplify both allelic-types.

The final stage of this work examined the genotypes and ‘rest-time’ clotting
properties of 75 thrombotic patients who presented for cardiac venografting.
Initially the viso-elastic properties of each subjects blood was studied using
thromboelastography (TEG).

Subsequently genotyping was performed using

SDM-PCR protocols to detect factor V Leiden, the prothrombin variant and other
mutations in the blood clotting pathway components of protein C and antithrombin
III. Comparisons between TEG and genotype data were made.
analysis has significant health economic implications.

XI
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Chapter 1
Introduction

1.1

Blood coagulation

Blood coagulation is activated in response to vascular damage and involves
intricate interaction between 'specific plasma proteins, platelets and vascular
endothelial cells (Virchows triad). The first step of the hemostatic process is the
activation of platelets which subsequently adhere at the site of vessel damage
isee Figure 1.1a). The platelets aggregate and form a platelet plug that blocks the
blood flow from the wound site.

Platelets also act as an organising surface

lacilitating the intrinsic coagulation cascade. Circulating proenzymes are activated
leading to the generation of the potent enzyme thrombin.

The latter converts

soluble fibrinogen into an insoluble fibrin that subsequently reinforces the platelet
plug (see Figure 1.1b). Thrombin also stimulates the release of Wiebel-Palade
bodies (endothelial storage granules), which contains von Willebrand factor as well
as P-selectin which further promotes platelet adhesion and aggregation (Spiess,
1997).

1.1.1

Initiation of blood coagulation

Blood coagulation is activated through the intrinsic pathway or the extrinsic
pathway (see Figure 1.2), culminating in thrombin formation.

According to the

currently accepted view, the intrinsic pathway plays an important role in the growth
?nd maintenance of fibrin formation while the extrinsic pathway is important in the
nitiation of fibrin formation (Davie et^., 1991; Davie, 1995; Hillarp^al., 1996).

(a)

Platelet Plug Formation
and
Coagulation Cascade

(b)

i

fibrin strands

Figure 1.1
A weak platelet plug will initially form at the site of vascular damage (a). The coagulation
cascade functions to generate fibrin strands that will bind and stabilize the platelet plug (b).

Intrinsic pi ocess

Extrinsic process

Kailikrein
HMW-kininogen

“V

Insohible fibrin

Figure 1.2
Schematic overview of the coagulation cascade.
Shown in this figure are the extrinsic (left side) and the intrinsic pathway (right side).
Activated clotting factors (except for thrombin) are designated by the lowe rcase a - i.e. Va, IXa etc.

Tissue factor (TF) is a phospholipid protein (Mr 37,000) located in the tissue
adventitia and is expressed and exposed to the blood after vascular damage
(Davie et al-, 1991). The exposure of TF to blood initiates the extrinsic pathway
forming a complex with factor VII in the presence of calcium ions (Furie et af., 1988;
Davie e\ ai-. 1991). This event facilitates the conversion of factor VII to factor Vila
after minor proteolysis. The combination of factor Vlla-TF activates factor X directly
which in turn also activates factor IX producing the ‘tenase’ complex (FIXa, FVIIIa,
Ca^"", phospholipid) which acts on factor X.
The newly generated factor Xa combines with factor Va in the presence of calcium
ions and phospholipid forming the prothrombinase complex. Finally this complex
enzymatically converts prothrombin to thrombin by the cleavage of two peptide
bonds (Jenny etal., 1987; Furie etai., 1988; Mann Mai-, 1990).

Factor Va participates as a co-factor in promoting additional prothrombin activation
by increasing the maximum velocity (Vmax) of the reaction some 1,000 fold resulting
in the generation of thrombin. Factor V is required in its active form to participate in
this reaction.

Initially this activation is catalysed by factor Xa, however after

thrombin is generated the latter will also activate factor V. In each case activation is
due to three peptide bond cleavages yielding the factor Va molecule (see Figure
1.3). The activated product factor Va is composed of a heavy chain (Mr 150,000)
and a light chain (Mr 74,000), the former binds prothrombin, whereas the light
chain anchors factor Va to the membrane (Kane

1987; Thorelli et^-. 1997).

709

Factor V

1018

1545

A1

Status:

Inactive
Thrombin JTactivation

306

506

Factor Va

679

: Ca2^:

inactivation

APC

Factor Vi

Active

; Ca2+:

Inactive

Figure 1.3
Factor V is a large single chain glycoprotein. It is composed of three homologous A-domains, one
B- domain and two homologous C domains. Thrombin cleaves the factor V polypeptide at three
sites, 709, 1018 and 1545 to produce activated factor V, (FVa). Factor Va is later inactivated by
activated protein C (APC). Proteolytic cleavage at Arg 506 is a rapid event, while cleavage at Arg
306 and 679 occur at a slower rate, producing an inactivated factor Va molecule (Factor Vi).

1.1.2

Growth and Maintenance of Fibrin Formation

The activity of the extrinsic pathway is short-lived due to the presence of inhibitors
and it is the intrinsic pathway that sustains the clotting pathway reactions
generating prothrombinase which permits continued growth of the fibrin clot.

The intrinsic pathway involves factor XII and factor XI (see Figure 1.2). Factor XII is
activated to factor XIla by the action of kallikrein and thrombin. Factor Xlla activates
factor XI (to factor XIa) the end result of which is the formation of the so called
‘tenase’ complex and the subsequent

activation of factor X to form the

prothrombinase complex.

Both the intrinsic and extrinsic pathways culminate in the explosive generation of
thrombin. This protein then binds to the central domain of fibrinogen and cleaves
fibrinopeptides A and B producing fibrin monomers. The fibrin monomers rapidly
polymerise to form long structural strands that cross-link forming a fibrin thrombus.
Pro- and anti-coagulant mechanisms are balanced in favour of anticoagulation
under normal physiological conditions.

In contrast, the anticoagulant system is

down regulated at sites of vascular injury and procoagulant forces prevail. This
delicate

balance

intravascular fluidity.

permits

extravascular

blood

clotting

whilst

maintaining

1.2

Regulation of blood coagulation

The coagulation system has considerable biological potential and strict regulation
is required. A number of inhibitory mechanisms exist to limit the size of any clot
formed and to prevent activated coagulation factors from entering the circulation
thus maintaining blood fluidity. There are three major inhibitory controls:
(1) Serine protease inhibitors (serpins),
(2) Tissue factor pathway inhibitor (TFPI) and
(3) the protein C pathway.

1.2.1

1.2.1.1

Serine Protease Inhibitors

Antithrombin III

Antithrombin III is an example of a serpin and is the most important inhibitor of
coagulation proteinases.

It circulates in plasma as a glycoprotein of molecular

weight 58 kDa. It is synthesised in liver and endothelial cells as a 432 amino acid
polypeptide (Bick, 1994; Perry M a}., 1996). The corresponding antithrombin gene
has been localised to chromosome 1q 23-25 (Bock ^

1985) and consists of

seven exons and six introns located over some 16 kb. Amino acid sequence and
structural homology studies suggest that antithrombin ill belongs to a large group of
related molecules, the serine protease inhibitor (serpin) family (Rosenberg ^
1973; Perry, 1994).

Antithrombin III is active against all of the activated serine proteases (Perry et aj.,
1996; Robbins et aj., 1997a), in particular thrombin and factor’s Xa and IXa. The
reactive site located towards the C-terminus forms a one to one complex with the
target serine protease. The rate of inhibition is greatly increased approximately
1,000 fold in the presence of sulphated glycosaminoglycans and heparin sulphate
(see

Figure

1.4),

which

bind

to

an

important

functional

domain,

the

glycosaminoglycan binding region.
In addition other plasma serine protease inhibitors that play a significant role in
regulating

blood

coagulation

include

heparin

cofactor II, a2-macroglobulin,

activated protein C (APC) inhibitor. Cl-esterase inhibitor and a^-antitrypsin.

1.2.2 Tissue factor pathway inhibitor (TFPI)
When compared to other clotting inhibitors TFPI is a recently identified inhibitor that
is generated during the activation processes (Rao M al-, 1987).

It functions by

forming an inactive complex with TF:FVIIa:FXa, inhibiting fibrin formation, thereby
downregulating the extrinsic pathway.

TFPI is a 276 amino acid polypeptide

containing three Kunitz-type inhibitory domains (Wun

1988). The first binds

to factor Vila, while the second binds to factor Xa.

TFPI does not block the

activation of factor XI thus allowing the continuation of the intrinsic pathway.

1.2.3

The protein C anticoagulant pathway

The protein C anticoagulant pathway provides an important measure of control
f

over the blood coagulation cascade, by regulating the activity of the pro-
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(a)

Heparin

AT HI

I
(b)

Heparin

AT HI

Figure 1.4
Antithrombin III is an important inhibitor of coagulation enzymes particularly thrombin and factors
Xa and IXa. Heparin binds to a lysine-residue on antithrombin III and facilitates accelerated binding
of target serine proteases.

coagulant co-factors Va and Villa (Stenflo, 1976; Kisiel, 1976) (see Figure 1.5). A
second function of this pathway is to promote thrombolysis by neutralising the
circulating inhibitor of tissue plasminogen activator, which leads to increased
fibrinolysis.

1.2.3.1

The protein C molecule

Protein C is a vitamin K dependent protein synthesised in the liver with a molecular
weight of 62 kDa (Bick, 1994; Reitsma et aj., 1995; MacHale M

1997),

consisting of two polypeptide chains, a 41 kDa heavy chain and a 21 kDa light
chain. Both are covalently linked yja a single disulphide bond (Dahiback, 1995a).
The light chain constitutes the y-carboxy glutamic acid (Gla) domain which interacts
with phospholipid, calcium ions and two epidermal growth factor (EGF)-like
domains. Protein C is a zymogen of a serine protease and it is the heavy chain
which is made up of the serine protease molecule (Foster ^ aJ., 1985). The gene
encoding protein C is located on chromosome 2(q 13-14). Nine exons spanning a
length of 11 kb, constitute the coding sequence.

1.2.3.2

Protein C-thrombomodulin-thrombin

Zymogenic protein C is proteolytically modified becoming an active serine
protease, known as activated protein C (APC). The activation step is catalysed by
thrombin in the presence of membrane bound co-factor, thrombomodulin (see
Figure 1.5) which increases the activation rate by 20,000 fold. (Esmon Mai-, 1982;
Esmon, 1989; Clouse et a}., 1986).

Without thrombomodulin the activation of

protein C is too slow to be physiologically significant.
10

Ca2+
APC

Pc

villa inactive

APC

V
0

Va inactive

I
Phospholipid surface

Figure 1.5
Thrombin interacts with transmembrane thrombomodulin (TM) leading to the activation of
protein C (APC). APC specifically inactivates the phospholipid bound factors Va and Villa in a
reaction accenuated by protein S and the intact form of factor V.

Thrombin bound to

thrombomodulin will eventually be inhibited by antithrombin or removed through endocytosis
of the thrombin/thrombomodulin complex.
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Thrombomodulin

is a single chain

glycoprotein

located on the surface

endothelial cells including arteries, veins, capillaries and

of

lymphatic vessels.

Binding of thrombin to membrane localised thrombomodulin modifies thrombin
activity, resulting in the loss of its procoagulant activity thus activating the protein C
pathway

(MacHale ^

1997).

In contrast thrombin generated at the site of

vascular injury activates the coagulation cascade (Zoller ^ ^., 1996).

Thus

thrombin has the ability to alter its status of activity from a procoagulant to an
anticoagulant depending on its interaction with thrombomodulin (Davies et
1991).

ARC can form complexes with protein S on the surface of endothelial cells and
platelets where it can promote the specific inactivation of factors Villa and Va by
limited proteolysis in the presence of calcium ions and phospholipid (see Figure
1.5). It has no effect on circulating factors V and VIII (Dahiback, 1994). Cleavage at
the light chain of factor Va occurs between Arg^^^^-Leu^^®®, without loss of functional
activity (de Stefano et a}., 1995; Hajjar, 1994). However proteolytic modification at
Argsoe, /^fg306

Arg®^® in the heavy chain (see Figure 1.3), is responsible for the

loss of functional activity and a decrease in the affinity for prothrombin and factor
Xa, (Guinto M aJ-, 1992). ARC inactivates factor Villa in the heavy chain at residues
Arg336, /^|^g502

Arg^°'* (Hoyer, 1994).

Factors Va and Villa serve as positive

feedback effectors on the coagulation cascade amplifying the effect of their
respective enzymes.

Their subsequent

inactivation

quenches

this

positive

feedback loop and halts the production of thrombi at the damaged vessel site.
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1.2.3.3

The protein S molecule

Protein S is a 71 kDa vitamin K dependent protein.

It is synthesised in

hepatocytes, vascular endothelial cells, megakaryocytes and by Leydig cells of the
testis (Hillarp e{ aj., 1995; MacHale e\ aj., 1997).

Two homologous genes for

protein S map to chromosome 3. Protein S a (PROS 1) the transcriptionally active
gene spans over 80 kb comprising 15 exons. The protein S (3 (PROS 2) gene
shows 97% homology with the coding sequence. However it is devoid of an open
reading frame (ORF) containing multiple base changes,

stop codons and

frameshifts. These features suggest that PROS 2 is a pseudogene (Aiach et ^.,
1995; Borge!

1996).

Protein S appears to exert its activity by enhancing the binding of APC to
phospholipid surfaces (Suzuki ^ a]., 1984). Factor Xa and APC compete for the
same binding site on factor Va, with factor Xa protecting Va from degradation by
APC.

However protein S removes this protective effect.

It has also been

suggested that protein S may have a direct anticoagulant effect through its
interaction with the prothrombinase complex (Heeb et aj., 1993). Approximately
60% of protein S in plasma is non-cova!ently bound to the C4b-binding protein
(C4BP). Only in the free form can protein S act as a cofactor. Thus C4BP can be
regarded not only as a regulator of the classical pathway of complement activation
but also as a regulator of the protein C pathway.

Recently intact factor V was

discovered to act as a second APC cofactor (Dahiback M a]., 1994; Shen et a}.,
1994).

Factor V co-operates with protein S to potentiate the APC-mediated

degradation of factor Villa and possibly factor Va in a manner not fully understood.
13

In addition factor Va stimulates the activation of protein C by thrombin and
thrombin-thrombomodulin, thus providing a suicidal component to the factor Va
amplification system (Salem et aj., 1984).

The physiological importance of the protein C anticoagulant system is illustrated by
homozygous deficiencies of protein S or protein C which are fatal in the neonatal
period due to massive thrombosis.

Heterozygosity for protein C or protein S

deficiency is known to be associated with a life-long increased risk of venous
thrombosis (Griffin M

1.3

1981; Bertina e\

1995).

Hypercoaguable States

Venous thrombosis is a serious health problem with an incidence of approximately
1 per 1000 annually (Goldhaber, 1994; Dahiback, 1994; Hillarp et aj., 1996). In the
United States, it accounts for 250,000 hospitalisations and 50,000 deaths annually.
It is uncommon in young individuals and the risk of thrombosis increases with
advancing age.

The most frequent manifestation is thrombosis of the deep veins of the leg which
may have serious morbidity, and occasionally death may result due to pulmonary
embolism (Rosendaal, 1994).

The disease occurs when activation of blood

coagulation exceeds the ability of the natural anti-coagulant factors and fibrinolytic
system to prevent fibrin formation.

Predisposing risk factors may be acquired or

genetic. The main acquired risk factors recognised are listed in Table 1.1 and the
14

mechanism underlying the hypercoaguable state in this group are poorly
understood.

However in some instances patients without these usual acquired risk factors suffer
from venous thrombosis which appears to be familial, this suggests the
involvement of a genetic risk factor (see Table 1.1). Until recently, the pathogenic
factors underlying thrombosis could only be attributed to quantitative and
qualitative deficiencies of antithrombin III, protein S and protein C. However these
were recognised in fewer than 5-10% of the thrombotic patients. Thus the vast
majority of thrombotic cases remained unexplained (Zoller

1996; Dahiback et

aj., 1996).

Table 1.1: Acquired and Genetic risk factors predisposing to venous thrombosis.
Genetic

Acquired
immobilisation

lupus anticoagulants

anti-thrombin III

pregnancy

oral contraceptives

protein C deficiencies

age

malignancy

protein S deficiencies

surgery

hormone replacement therapy

factor V Leiden

pueroerium

anticardiolipin antibodies

factor II 2021OA

trauma

obesity

dysfibinogenemia

However a breakthrough was made in 1993 with the discovery of resistance to
activated protein C (Dahiback

1993; Hajjar, 1994; Bertina et aJ-. 1994). ARC

resistance (APCr) is now recognised as the most prevalent coagulation
15

abnormality associated with venous thrombosis, (Koster et a]., 1993; Beauchamp et
aj., 1994; Voorberg ^ aj., 1994; Sun_et^., 1994; Dahiback, 1995a), occurring in an
estimated 20-65% of patients with a history of familial venous thromboembolism,
and making it at least 10 times more frequently than other known coagulation
abnormality {Hajjar, 1994; Svensson Mai-, 1994).

Furthermore this abnormality

was also reported in the asymptomatic general population at a prevalence of 3-7%,
(Bertina et

1994; Dahiback, 1995b; Kirschbaum et al., 1995).

A genetic variant in the prothrombin gene (factor II) was described in 1996 (Poort
et aJ-, 1996) resulting in a G to A transition mutation at nucleotide position 20210 in
the 3’-untranslated region (UTR) of the gene. Acquisition of this mutation increases
the level of prothrombin in plasma which in turn is associated to an increased risk
of thrombosis (Rosendaal

1997a; HillarpMal., 1997; Bertina, 1997; Makris et

ai., 1997). The prevalence of the prothrombin 3’-UTR mutation is estimated at
about 2% in healthy controls and 6% in unselected consecutive patients with deep
vein thrombosis (Rosendaal et

1997b; Brown Maj., 1997). These two genetic

abnormalities are found much more frequently then other known causes of
inherited thrombophilia.

1.3.1

Antithrombin deficiencies

Antithrombin deficiency is inherited as an autosomal dominant trait and was first
described in 1965 by Egeberg. Two main types have been described denoted as
types I and II and these are recognised as a' risk factor associated with the early
development of venous thromboembolism. Affected individuals with type I disease
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present with primary venous thrombi and decreased antithrombin levels.

This

disease is inherited as an autosomal dominant trait with heterozygotic individuals
having an increased risk of venous thrombosis (Baglini, 1990; Bertina, 1997). At
present a catalogue of 184 different mutations in the antithrombin gene have been
reported (Lane ^al., 1992, 1993 and 1994).

Type I deficiency has only been identified in heterozygotic individuals and is
characterised by a reduction in immunological and functional plasma antithrombin
levels (usually to approximately 50% of normal). This finding suggests that one
mutant antithrombin allele fails to direct the synthesis of detectable protein (Olds et
a]., 1993). Furthermore type I deficiencies may also result from a wide variety of
heterogenous

mutations including

gene

deletions

or insertions,

frameshift

mutations, missence, nonscence and splice site mutations. (Bick, 1994).

Type II deficiency is characterised by normal immunological antithrombin levels
but functional levels are reduced, suggesting the presence of a variant protein in
the plasma of affected patients. Type II deficiencies result from point mutations and
can be classified into the following groups; mutations affecting (i) the heparin
binding site (HBS), (ii) the reactive site (RS), (iii) the proximal and distal hinge
regions and (iv) the C terminal polypeptide domain (Perry M aj., 1996). Type II
HBS variants are known to be associated with only a mildly increased thrombotic
risk, except when there is no corresponding normal allele (ie: homozygous
affected).
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The essential clinical features of antithrombin deficiency include, a family history of
thrombosis, thrombosis during pregnancy and thrombosis resistant to heparin
therapy. Thrombosis usually occurs in the deep veins of the legs or manifests as a
pulmonary embolism. However the latter may also occur at unusual sites such as
mesenteric, renal and cerebral veins (Hirsh, 1981).

The risk of thrombosis

increases with age, with the peak incidence occurring between the ages of 15 and
40. Heterozygosity for antithrombin deficiency can be found in 4% of families with
inherited thrombophilia, in 1% of deep vein thrombosis patients and in 0.02% of
healthy individuals (Bertina, 1997).

1.3.2

Protein C deficiency

Protein C deficiency was first reported in 1981 by Griffin et al.

In families with

thrombophilia, this deficiency is inherited as an autosomal dominant disorder. Two
types of inherited protein C deficiency exist;

Type

I is the most common and is characterised by a reduction in both

immunologic and biological functioning of the protein due to reduced synthesis.
Protein C deficiency is genetically very heterogenous with greater than 160
different mutations characterised (Reitsma ^ a]., 1995).

in a data base listing

mutations for type I deficiency 65% constituted missence mutations, 24% vyere
nonsense mutations, 7% were frameshift mutations, 2% had splice site defects and
a further 2% had mutations in the promoter region.
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Type II deficiency is less common and is characterised by normal protein C
antigen levels but with decreased functional activity. Type II mutations result from
amino acid replacements (Bick, 1994).

A minor subgroup of protein C deficient subjects may clinically express protein C
deficiency thus developing venous thrombotic complications (Owada et a]., 1992;
Gandrille et aj., 1992). The most common sites of thrombosis are the superficial
veins which may lead to pulmonary embolism. Heterozygotic individuals may also
have an increased risk of developing warfarin-induced skin necrosis.

The

frequency of this clinical trait is estimated currently at 1 in 15,000 in the general
population (Miletich, 1990). However there is also a recessive protein C type I and
II deficiency in which the subjects are asymptomatic, with a frequency of 1 in 200300 in the general population (Miletich et aj., 1987).

One factor that may influence a protein C deficient individual being symptomatic is
whether they are also a carrier of the factor V Leiden mutation (Hallam eX a1., 1995;
Reitsma ^ aj., 1995). This variant occurs in up to 19% of patients with protein C
deficiency as compared with a 3% incidence in healthy individuals (Koelman M al-,
1994).
A unique syndrome of purpura fulminans has been described in homozygous or
compound heterozgous patients (Marlar et aj., 1989).

It is usually fatal as they

develop massive thrombosis during the neonatal period (Gandrille Mai-. 1993 and
1995a). However if fresh frozen plasma or factor IX concentrates given together
with heparin is administered rapidly, patients do respond (Bick, 1994).
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Finally acquired protein C deficiency has been reported. This disease is found in
association with liver disease, disseminated intravascular coagulation, severe
infection, adult respiratory distress syndrome, postoperative trauma and after
certain chemotherapy agents (MacHale Mai-, 1997).

1.3.3

Protein S deficiency

Hereditary protein S deficiency is an autosomal dominant disorder which was
originally described by Comp M M-, (1984).

Heterozygous individuals have a

strong tendency to develop deep vein thrombosis, superficial thrombophlebitis and
pulmonary embolism (Bick, 1994; MacHale M aj-, 1997).

Some individuals may

also experience arterial thrombotic and thromboembolic events (Allart M

1990).

Independent inheritance of protein S deficiency and activated protein C resistance
have also been reported (ZollerMaj-, 1995).
About 50% of protein S deficient patients have their first thrombotic event by age
25.

However, heterozygous individuals exist that do not appear to have an

increased predisposition to deep vein thrombosis possibly representing an
asymptomatic deficiency state. Homozygotes however are severely affected and
may develop a form of purpura fulminans shortly after birth (MacHale Mil-, 1997).

Protein S deficiency exists in three different forms (Bick, 1994; Simmonds M
1996; Yamazaki M^-, 1996).
Type I deficiency is defined as a quantitative defect, (i.e.: reduction in both total
and free protein S levels).
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Type 11 deficiency is caused by a dysfunctional protein S molecule characterised
by reduced activity with normal levels of free and total protein S antigen
(Qualitative deficiency).
Type III deficiency is characterised by decreased levels of functional active free
protein S antigen with normal levels of total protein S antigen (Selective
deficiency). It has been reported that types I and III deficiencies are phenotypic
variants of the same genetic disease (Zoller^al., 1995).

Molecular analysis of protein S deficiency has not advanced rapidly for many
reasons (Gomez ^ aj., 1995). Firstly the interaction between protein S and C4Bbinding protein (C4BP) complicates the analysis of protein S deficiency. Secondly,
it may be due to the relatively recent characterisation of the protein S gene in 1990.
Also the presence of the pseudogene PROS 2 confounds genetic investigation.

Protein S deficiency is genetically heterogeneous. Almost 70 different mutations in
the PROS 1 gene have been identified (Aiach

1995). These mutations range

from deletions of large areas of the gene, to single base changes and frameshifts
within the exons and splice sites (Reitsma ^ af., 1994; Gandrille ^ af., 1995a;
Gomez et ^., 1995). The majority of protein S deficient patients have the type I
deficiency (Bertina, 1997). In families with inherited thrombophilia the prevalence
of protein S deficiency type I is 6% and 1-2% in patients with a first deep vein
thrombosis occurrence.

Cork Institute of Technology
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Acquired protein S deficiency is associated with oral anticoagulant medication,
pregnancy, disseminated intravascular coagulation (DIG), acute thromboembolic
disease and the use of oral contraceptives.

1.3.4

Activated protein C and factor V Leiden

The discovery in 1993 of resistance to activated protein C in a middle aged man
with familial thrombophilia and a poor in vitro anticoagulant response to APC was
a major breakthrough (Dahiback Mai-, 1993; Hajjar, 1994; Bertina et aj., 1994).
Substitution experiments performed by Dahiback M aJ., (1994) implicated factor V
as the underlying cause of APCr.

This observation taken together with the

demonstrably close genetic linkage between the factor V gene and the APCr
phenotype suggested that this genetic defect may map in the factor V gene.
Plasma mixing experiments supported this observation wherein APCr was found to
be corrected by all coagulation-deficiency plasmas except when factor V was
deficient (Koster e\ ^., 1993; Bertina M aj., 1994; Sun et aj., 1994; Dahiback,
1995b; Zoller^aJ., 1996). The genomic location of the factor V gene was mapped
to human chromosome 1 (q21-25) (Wang ^ ^., 1988).

Its genomic organisation

consists of 25 exons ranging in size from 72 to 2820 bp and with 24 introns ranging
in size from 0.4 to >11 kb (Cripe Mai-. 1992).
Genomic analysis identified that the APCr phenotype was associated with a
guanidine (G) to adenine (A) transition mutation occurring at nucieotide 1691 in the
3’-region of exon 10 (Bertina et aj., 1994).

This mutation elaborates factor V

molecule (factor V Leiden) wherein Arg(506) [CGA] was substituted by Gin [CAA]
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(Dahiback et aj., 1993; Koster ^ al., 1993; Bertina M al., 1994; Greengard et ai.,
1994; Kalafatis et ai., 1994; Voorberg et

1994; Zoller ^ai., 1994a and b). This

mutation results in the loss of an ARC cleavage site at residue 506 (see Figure 1.6).
Inactivation of membrane bound factor Va involves three sequential proteolytic
events. The ARC cleavage at Arg 506 is required to expose the subsequent sites
at Arg 306 and 679 (Kirschbaum et aj., 1995). With the loss of the ARC cleavage
site at residue 506, the latter proteolytic events result in the inefficient inactivation of
factor Va. It is estimated that the rate of inactivation of FVa:Q506 by ARC is 10 to 20
times lower than the rate of FVa:R506 degradation (Zoller ^ af., 1996; Kalafatis et
al., 1994; Heeb M aJ-. 1995). Thus mutated factor Va is associated with an increase
in thrombin generation, resulting in a hypercoaguable state (Zoller etaj., 1996).

1.3.4.1

Prevalence and clinical significance of activated protein C

resistance
ARCr appears to be inherited as an autosomal dominant trait, suggesting the
involvement of a single gene (Beauchamp ^ ^., 1994; Koeleman et aj., 1994;
Braun e\ 3^., 1996).

A homozygous abnormal individual is known to have a

significant thrombotic risk compared to a heterozygous individual.

Heterozygotes

are associated with a 5-10 fold increased risk of thrombosis whereas, homozygotes
are associated with a 50-100 fold increased risk (de Stefano et a]., 1995; Dahiback,
1995b; Rees ^ ^., 1995).

The prevalence of the mutation in the general

population of Western countries varies between 2 and 15% (Dahiback, 1995b),
with more than 95% of ARCr cases attributed to this point mutation.
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Figure 1.6
Activated protein C resistance is caused by the Arg (R) 506 to Gin (Q) replacement in the APCcleavage site of factor Va.
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Table 1.2 illustrates the world wide distribution of the factor V Leiden mutation
among some of the worlds populations.

Owing to the high prevalence of factor V Leiden in Western populations, it may
occasionally occur in patients with deficiencies in protein S, protein C, or
antithrombin III (Dahlback et al-, 1994; Koeleman Ma].. 1994; Hallam ^ a}.,1995;
Reitsma et al., 1995; ZollerMa]., 1995). Those individuals with combined defects
suffer more severely from thrombosis and often at a younger age, than those with
single gene defects, suggesting severe thrombophilia to be a multigenetic disease
(Dahlback ^ a}., 1994 and 1996; de Ronde M a]., 1994; Koeleman et a}., 1994;
Zoller et ^., 1996). The clinical manifestations of APCr are similar to those of the
protein C, protein S, or antithrombin III deficiencies, deep venous thrombosis of the
lower limbs with or without pulmonary embolism and superficial thrombophlebitis
(Bick, 1994; Zoller M aj., 1996) being the most common features. A few cases of
haemolysis elevated liver enzyme and low platelet count (HELLP) syndrome
(Brenner M a]., 1996), portal vein thrombosis (Levoir
thrombosis (Linna M

1995) and retinal vein

1997) have also been reported in patients with APCr. In

stroke and cardiac disease patients the low prevalence of APCr (Holm e\ aj., 1994;
Samani et al., 1994; Syrjala et aj., 1995; de Lucia et

1996; Nowak-GottI et a].,

1996) suggests that it is not a major risk factor in the pathogenesis of arterial
disease, (Dahlback j^aj., 1994; Heinrich

1995; Prohaska et al-. 1995; Ridker

et aJ., 1995; Zoller et ii-. 1996). However a recent report has shown that factor V
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Table 1.2: Detection of the prevalent G1691A mutation among healthy populations of diverse
ethnic backgrounds.
Country

Prevalence (%)

Reference

United Kingdom

1.7

Beauchamp et al., 1994

5.6

Catto et al., 1995

Belfast (UK)

5.9

Emmerich et al., 1995

Southern Sweden

15

Dahiback et al., 1996

Finland

2.9

Kontula et al., 1995

Netherlands

2

Bertina et al., 1994

Holland

2

Rees et al., 1995

Portugal

0.8

Ferrer-Antones et al., 1995

Spain

3.3

Garci'a-Gala et al., 1997

Poland

5

Herrmann et al., 1997

Germany

2

Rees et al., 1995

North-East Germany

3.5

Schroder et al., 1996

South Germany

2-7

Braun et al., 1996

Iceland

2.6

Rees et al., 1995

Greece

7.0

Rees et al., 1995

Italy

nd

Rees et al., 1995

1.87

Pepe et al., 1997*

Australia

nd

Rees et al., 1995

Africa

nd

Rees et al., 1995

Asia

nd

Rees et al., 1995; Chan et al., 1996

China

0-0.1

Ko et al. and Yiqun et al.,1996**

Japan

nd

Fujimura et al., 1995*

Asia Minor

0.6

Rees et al., 1995

4

Gou et al., 1996*

Greenland Eskimo

nd

de Maat et al., 1996

Peru (Indians)

nd

Rees et al., 1995

South East Brazil

2

Arruda et al., 1995*

Argentinia

5

Herrmann et al., 1997

nd-not detected
Table notes:
* Allelic analysis reported by these authors suggested that the mutation may be independent of
ethnic background. ** Yiqun et al., 1996 showed that 4% of normals and 14% of DVT cases among
the Chinese were found to be APCr.

However the most common G1691A mutation was not

detected. These authors suggested that auto-antibodies to APC may be the cause for APCr in China.
It should be noted that other as yet undefined mutations in the factor V and factor VIII genes should
be considered in the future to explain this observation.
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Leiden is associated with myocardial infarction in young women and that the risk
was increased further in subjects who were smokers (Rosendaal Mil-, 1997b).
The risk of thrombosis increases with senescence, but most individuals who are
heterozygous appear to have a lowered risk as a function of age compared with
those who are heterozygous with deficiencies in other coagulation linked genes.
Homozygous individuals experience thrombosis at a markedly younger age
(Rosendaal

1995), with a median age of 31 years compared with 44 years in

the heterozygous and 46 years in the normal patient population.

However this is

more apparent when patients are exposed to situations known to be associated
with increased risk of thrombosis such as surgery (Fauno ^ aj., 1995), pregnancy
(Bauer, 1995; Conard M ^., 1995; de Stefano et aj., 1995), the use of oral
contraceptives (0sterud et a]., 1994; Vandenbroucke et a]., 1994; Bloemenkamp et
^., 1995; Conard

1995; de Stefano ^ aj., 1995), or immobilisation (Ridker et

aj., 1995; Rosendaal ^ ^., 1995). Recent data indicates that 60% of women who
develop a first episode of venous thrombosis during pregnancy are also APCr,
(Bauer, 1995; Conard et ai-, 1995; de Stefano Maj., 1995). Similarly a woman who
uses oestrogen/progestagen oral contraceptives and is a heterozygous carrier will
have a risk of venous thrombosis some 30-50 times greater than that of a non-user
who does not carry the mutation. ARC resistance may be a major pathogenic factor
predisposing to postoperative thrombosis.

Of patients developing deep vein

thrombosis after knee arthroplasty 30% have been reported to be ARC resistant
(Fauno etaj., 1995). Once the APCr phenotype has been diagnosed, special care
must be taken to prevent thromboses associated with risk situations.
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1.4

Laboratory diagnosis of activated protein C resistance
and other clotting factor abnormalities

1.4.1

Thromboelastography

Conventional coagulation screens (activated clotting time, prothrombin time, aPTT,
thrombin time, etc.) are frequently inadequate for monitoring coagulation when
there may be many potential haemostatic defects.

Thromboelastography is a

simple and sensitive technique discovered in 1948 by Hartet that overcomes this.
The thromboelastogram (TEG) is an accurate test for the study of coagulation from
the formation of the first fibrin strands to clot dissolution.

It also has the ability to

measure the viso-elastic properties of the blood clot.

Overall this method can

assess both the quantity and quality of blood clotting. The TEG instrument provides
a valuable tool for the study of bleeding disorders and in the assessment of the
effects of anticoagulant drugs. For example anesthethiologists have been making
TEG

measurements

hemorrhagic

potential.

on

patients

undergoing

It has also been

procedures

with

used to identify and

significant
measure

hypercoagulability.

1.4.1.1

Principles of the TEG instrument

A cylindrical cup maintained at 37°C contains the blood sample to be analysed. A
pin is lowered into the blood by a torsion wire (see Figure 1.7) (Haemoscope,
1990; Chandler, 1995). The cup is oscillated through an angle of 4°45’ in order to
measure the elastic shear modulus of the clotting blood.
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The torque of the cup

affects the pin after fibrin-platelet binding has linked the cup and pin together. The
magnitude of the pin motion is affected as the clot forms, and the stronger the clot
the more the pin moves with the cup. Thus the magnitude of the output is directly
related to the strength of the formed clot (Greilich ^af., 1997).

electromagnetic
transducer

Fibrin /platelet strands

Whole Blood

Cylindrical cup

Figure

1,7

Diagram of the thromboelastogram instrument.

In the early instrument designs, rotation of the pin was recorded using a mirror
attached to the pin, a light beam and photographic film (Chandler, 1995). However
current models contain a rnechanical/electrical transducer and amplifier which
drive a pen motor producing immediately usable tracings on heat-sensitive paper.
There are also instruments such as the TEG Coagulation Analyzer Model 3000C,
in which the output is converted to digital data for display on a computer terminal
(see Figure 1.8). This provides the user with a prompt and accurate analysis of the
coagulation and lytic patterns produced by the TEG. The computer stores,
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Figure 1.8

Diagram of the computerized TEG® Coagulation Analyzer (TEG™) Model 3000C. The instrument contains
an interface box which connects the TCG to the computer. The interface box contains a board that converts
the analog signals from the TEG to digital signals.

(a)

(b)

Normal

Hen>oph«Ua
fibriootysis
Thrombocytopenia
Hypercoa«uUtion

Figure 1.9
(a) A typical TEG tracing representing the five standard measurenients.
measurements is described in Section 1.4.1.2.
(b) Thromboelasographic tracings of normal and disease states.
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Interpretation of these

displays, analyzes and prints both the coagulation profile and the data derived from
the profile.

1.4.1.2

TEG tracing

A number of parameters are measured from the TEG trace (see Figure 1.9a)
(Chandler, 1995; Traverse e\^., 1995; Robbins ^ aj., 1997b). These include the
following:
(a) The reaction time (R) is measured from the start of tracing to the point where the
curve is 1 mm wide. This is the time to clot formation and is normally 6-9 minutes.
Such a measurement provides information on thrombin generation, therefore it is
influenced by factors that belong to the intrinsic pathway and increases linearly
with increasing thrombin concentration.

(b) The coagulation time (K) is the distance from the 1 mm wide point to the 20 mm
wide point.

It represents the speed at which a certain level of clot strength is

reached and is normally 3-5 minutes. This measurement describes both thrombin
activity and fibrin formation. The divergence angle (a) is measured between the
midline of the tracing and a line drawn from the 2 mm wide point tangential to the
curve. It denotes the kinetics of clot growth and is normally > 55°.

K and a both

measure similar information and are affected by the availability of fibrinogen and by
the presence of factor XIII and to a lesser extent, by platelets which enables crosslinking.
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(c) Maximum amplitude (MA) is the width of the curve at its widest point and
represents the maximum clot elastic shear modulus available. It is normally 40-60
rrm. MA is influenced by platelet function and number, by fibrinogen and thrombin
concentration, fibrin, factor XIII and hemocrit. The Ago value provides a measure of
the rate of amplitude reduction 60 minutes after MA and represents the ultimate clot
stability.

1.4.1.3

Interpreting the TEG trace output

The TEG parameters shown in Figure 1.9b can be used to highlight haemostatic
problems.

.An elongated R value is associated with factor deficiencies or

inhioitors/anticoagulants (e.g. heparin). Thrombocytopenia is indicated when R is
elongated and K lengthens. Afibrinogenemia generates a TEG characterised by a
prolonged R-value with absence of other constants.

All parameters will be

modified if there is hypercoagulability such as in the case of APCr. This is typically
cha'acterised as R-time < 4 minutes, K-time < 1 minute, a > 60° and/or a MA of > 70
mm (Robbins ^

1997b).

The identification of hypercoagulability in surgical

patients is important since it represents a major risk factor for developing venous
thrcmboembolism (Arcelus ^aj., 1995).

The TEG provides a rapid and objective measure of the changes in the viscoelastic
proDerties of blood from the formation of the first fibrin strand to the dissolution of
the clot. Thus it allows a complete evaluation of the process of clot formation and
the structural characteristics of the formed clot and its stability. Routine laboratory

32

tests are normally performed on plasma fractions and examine only isolated
portions of the coagulation cascade.

Many conventional tests end with the

formation of a fibrin strand while TEG begins at this point and continues to generate
data through to clot lysis (Mallet et aj., 1992; Caprini ^ a]., 1995).

The main

disadvantage associated with TEG tracing compared to conventional methods is its
inability to specify clotting abnormalities such as APCr. factor V or factor IX
deficiency.

1.4.2

Coagulation based assays

Many coagulation based assays for the detection of activated protein C resistance
have been described and are commercially available (de Ronde ^ a]., 1994;
Kirschbaum et a]., 1995; Aboud et a}., 1997; Gable ^ a]., 1997).

1.4.2.1

Standard aPPT Method

The most common commercially available test for the measurement of APCr
depends on the anticoagulant response of the blood sample to exogenously added
APC in an activated partial thromboplastin time (aPPT)-based method (Dahiback,
1995a). In an aPPT assay, addition of APC results in degradation of factors Villa
and Va, delaying the thrombin burst. However in a factor V Leiden patient APC will
not completely degrade activated factor V resulting in an increased rate of thrombin
generation giving a shorter aPPT. The difference in the APC response times of
normal and abnormal/mutated factor Va is evident.
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The standard screening kit for the APC resistance phenotype, COATEST® APC™
Resistance, relies on the determination of two aPPT estimations using the patients
plasma, one in the absence of APC and the other in the presence of a fixed amount
of exogenously added APC.

Calcium chloride is present in both reactions to

initiate the clotting cascade. The relationship between the two aPPT values is
usually expressed in the following ratio:.
APC ratio = aPPT + APC
aPPT
APCr is determined when the .APC ratio is below or equal to a cut off value defined
as a mean ratio minus 2 standard deviations (see Table 1.3).

Table 1.3. Typical APC ratios obtained using the COATEST® APC™ Resistance
kit.
Factor V Genotype

APC ratio

Normal (G/G)

>2.5

Heterozygote (G/A)

< 2.3

Homozygote (A/A)

< 1.5

The standard APCr test has a sensitivity of 76% and specificity of 98% for the factor
V Leiden mutation in a group of patients with venous thrombosis.
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1.4.2.2

Diagen PCA Test

A modification to the standard aPPT coagulation assay is the Diagen PCA-based
assay (Diagnostic Reagents Ltd., Oxon, UK). Protein C in the presence of protein S
may be activated to APC by protein C activators (PCA), either thrombinthrombomodulin or by venom fractions from various snakes including Aokistrodon
contortrix (Denson e\ aj., 1996).

APC is generated by endogenous protein C,

protein S and APC cofactor when PCA is added to the patients plasma.

APC

subsequently inactivates factor Villa and Va. In the presence of normal protein S
and protein C levels it becomes unnecessary to use preformed APC and the
addition of PCA will detect APCr. This assay format can also be used to detect
protein S and protein C defects (Denson Ma!-, 1996).

In this Diagen-PCA based test, plasma is incubated with an aPPT reagent with and
without PCA and the clotting time is determined by the addition of calcium chloride.
The clotting time ratio of PCA-aPPT/aPTT is then determined. In general ratios <
2.2 indicate APC resistance. This technique and others such as the Russel Viper
Venom time (RVVT)-based system (Aboud e\ ^., 1997) have shown greater
specificity and sensitivity for factor V Leiden detection compared to the standard
aPPT based method (Maher eta]., 1998/1999a).

1.4.2.3

Advantages of coagulation based assays

Coagulation based assays are relatively cheap and easy to perform. They can be
performed in virtually any modest clinical laboratory. The APC ratio indicates the
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severity of the APC resistance and can also detect thrombosis prone APC resistant
cases without the factor V Leiden mutation (Dahiback, 1995b). Both assays can be
performed on fresh or frozen plasma.

1.4.2.4

Limitations of coagulation based assays

APC resistance may be acquired through antiphospholipid interference in the
protein C pathway, thus mimicking a factor V Leiden phenotype.

Lupus

anticoagulant and anti-cardiolipin antibodies are acquired antibodies described in
patients with systemic lupus erythematosus (SLE).

These antibodies react with

anionic phospholipid thus preventing the degrading effect of APC on factors Villa
and Va. This tendency may produce a prolonged clotting time and may influence
the APC ratio, decreasing it. APPT-based screening cannot be used on patients
possessing these lupus anticoagulants (Maher ^ af., 1997).

In contrast the RVV

reagent is rich in procoagulant phospholipid, neutralising inhibition due to lupus
anticoagulant antibodies thus rendering this method suitable for patients with lupus
anticoagulants.

Both tests are not reliable when performed on oral anticoagulated plasma (OAC)
due to reduced concentrations of procoagulant

prothrombin

and factor X.

Heparanised plasma may also disturb the reliability of both tests. These problems
have been overcome using modifying predilutions on test plasmas (Jorquera e\ a].,
1996; Aboud

1997). This modification allows correction of the deficiency of

vitamin K dependent factors without affecting the endogenous level of factor V in
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patients taking OACs.

Using this procedure the sensitivity and specificity for the

factor V Leiden mutation is increased to about 100% (see Figure 1.10 taken from
ZollerMai-, 1996).

These coagulation based screening methods require careful standardisation of
both sample handling, transportation, choice of reagent and instrumentation.
Problems may arise with these tests as a certain number of cases may fall within
the borderline zone (Kirschbaum e\ aj., 1995).

For such samples a rapid and

accurate DNA-based assay would be preferable to the coagulation based format
(Maher

Figure

1997).

1.10

COATEST® ARC™ Resistance using the standard method compared to the modified method (plasma
prediiuted 1 + 4 with V-DEF plasma). The standard method detects thrombosis-prone individuals with
unknown mutations and indicates the severity of APCr. The modified method provides discrimination

for the factor V: R506Q mutation and permits analysis of plasma from patients on oral
anticoagulants or heparin therapy. [DEF= deficient].
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1.4.3 Polymerase Chain Reaction (PCR)
The development of the polymerase chain reaction (PCR) in 1985 by Mullis and
Faloona has made a significant impact on biological research.

It was originally

applied to amplify part of the human p-globin gene and in the prenatal diagnosis of
sickle cell anemia (Saiki M M-, 1985).

Since then the number of applications

reported for PCR together with novel design modifications has grown exponentially
(Fanning and Gibbs, 1997).

1.4.3.1 Amplifying genomic targets
The polymerase chain reaction is an in vitro technique designed to amplify a specific
DNA fragment (see Figure 1.11). The method is both elegant and simple requiring
only three thermal steps; denaturation of duplex DNA at 92-96°C, annealing of the
two specific oligonucleotide target-specific primers to a complementry site on the
genomic template at 55-72°C and extension of the above primers by a thermostable
DNA polymerase at 72°C. These three steps represent one PCR cycle, creating two
double stranded target regions. Typical PCR reactions comprise 25-35 cycles,
leading to a rapid exponential accumulation of the specific DNA fragment,
(approximately 2" where n is the number of cycles used).

1.4.3.2 Parametric considerations for thermal profiling
Denaturation
Initially a PCR reaction may involve a heating step at 92-96°C for 3 to 5 minutes to
completely denature the DNA template. However to prevent loss of enzyme
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1.11

Schematic diagram of the polymerase chain reaction.

In the first cycle, the two strands of DNA

template are separated and oligonucleotide primers are annealed at sites opposite each other. The
primers are extended by DNA polymerase to copy a region including the sites bound by the opposing
primer. After the first cycle, fragments with a 3’-end defined by the end of the template fragment are
synthesised. After many cycles these predominate, giving rise to a double-stranded DNA product
with a length defined by the 5’ positions of the two opposing oligonucleotide primers
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activity the subsequent cycles involve shorter denaturation times at 95°C.
temperatures may be appropriate in some instances

Higher

especially for G+C rich

targets. Incomplete denaturation may cause the DMA strands to “snap back” and
this leads to reduced product formation.

Primer annealing
The temperature and time required for primers to anneal to template DMA depends
upon the base composition, length and concentration of the primers.

Generally

annealing is carried out at 5°C below the melting temperature (TJ of the primers.
The equation outlined below calculates the T^ for oligonucleotides of 10-20 base
pairs (bp) in length (Binnie, 1991).

T, = 2(A+T) + 4(G+C)

Annealing temperatures in the range of 55 to 72°C for 20-40 seconds yield the
optimal results.

Increasing the annealing temperature will decrease the risk of

primers annealing to incorrect sites and reducing non-specific priming and
misextension of incorrect template positions at the 3’-end of the primers (Innis e\ a}.,
1990). Stringent annealing temperatures will increase specificity.

In vitro enzyme-mediated primer extension
Primer extensions are normally performed at 72°C for one minute for products

40

up to 2 kb in length (Innis et ai-, 1990). The enzyme used to catalyse this step is a
thermostable DNA polymerase (see Table 1.4 and Section 1.4.3.3).

Table 1.4: Thermostable polymerases available for polymerase chain reaction
Thermostable
polymerase

Source

Characteristics

Tag DNA polymerase

Thermus aqauticus

exhibits 5’-^3’ exonuclease
activity

Vent DNA polymerase

Thermococcus litoralis

exhibits 3’-^5’ exonuclease
activity

Pfu DNA polymerase

Pvrococcus furiosus

exhibits 5’-^3’ and 3’->5’
exonuclease activity

Ultma DNA polymerase

Thermotooa maritime

yields high fidelity PCR
products suitable for cloning

rTth DNA polmerase

Thermus thermoohilus

exhibits reverse transcription
activity

Cycle number
The optimum number of cycles will depend on the starting concentration of
template DNA. Normally cycle numbers ranging between 25-35 are appropriate. It
should be noted however that the amplification rate adjusts from an exponential to
linear (“plateau” effect) array as the amount of product exceeds DNA polymerase
concentration. The “plateau” begins at approximately the 25th cycle after 4x10®
fold amplification of target DNA (Saiki et af., 1988). Too many cycle numbers (> 40)
may lead to an increase in the amount of amplification artefact(s).
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Final extension
Normally after the last cycle a 5-15 minute “hold” at 72°C is carried out to facilitate
completion of partially extended products remaining in the reaction and complete
the annealing of single-stranded complementary products.

1.4.3.3

Tag Polymerase

The original PCR reaction used the Klenow fragment of Eschericia coli
polymerase (Mullis ^

1985).

DNA

However this enzyme is thermolabile so fresh

enzyme had to be added into the reaction tube after each cycle due to the
denaturation step. The introduction of a thermostable DNA polymerase from the
thermophilic bacterium Thermus aquaticus (Tag) transformed the PCR into a robust
and simple reaction (Saiki etM-, 1988). The recommended concentration range for
Tag DNA polymerase is between 1 and 2.5 units per 100 pi reaction volume (Innis
etal., 1990). Tag DNA polymerase has a high optimum temperature of 75-80°C
with an extension rate of 150 nucleotides/sec/enzyme molecule. At temperatures >
90°C it yields little or no DNA synthesis, however it remains stable and functionally
active. The enzymes cycling half life (number of cycles reguired to observe a 50%
decline in activity) would be reached after 50 cycles when the upper temperature
limit is 96°C for 15 seconds in each cycle.

The enzyme is sensitive to

concentrations of Mg^^ and dNTP’s. A concentration of 2.0 mM MgCl stimulates
2

Tag DNA polymerase at 0.7-0.8 mM dNTP (Saiki et a}.,

1988).

Higher

concentrations of Mg^^ are inhibitory with 40-50% inhibition at 10 mM MgCl .
2
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Tag DNA polymerase exhibits a 5’-3’ exonuclease activity but lacks the 3’-5’ proof
reading ability.

Compared to Klenow for a PCR reaction of 30 cycles the

misincorporation rate for the latter per nucleotide per cycle is estimated at 2 x
10'" lower.

Since the original description of Tag DNA polymerase, several

additional thermostable enzymes have become available.

These together with

their relevant characteristics are described in Table 1.4.

1.4.3.4
The

Deoxynucleotide triphosphates (dNTPs)

optimal

deoxynucleotide

triphosphate

(dATP,

dCTP,

dGTP,

dTTP)

concentrations for a PCR reaction was estimated at between 50-200 pM each.
Higher concentrations (>1.5 mM) or an imbalanced dNTP concentration increases
misincorporation errors giving rise to point mutations at least (Innis M al., 1990).
Low dNTP concentrations decreases mispriming at non-target sites and reduces
the likelihood of extending misincorporated nucleotides.

1.4.3.5

Primer

Normally primer concentrations between 0.1 and 0.5 pM are recommended for
successful reaction completion.

Higher primer concentrations may give rise to

mispriming and accumulation of non-specific amplicons.

Generally it is the

seguence and the combination of the primers that determine the success of the
PCR. A few guidelines exist aimed at facilitating primer design (Innis ^ ai., 1990;
Fanning and Gibbs, 1997):
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• Normal primer length of 18-30 nucleotides with a G+C content ranging from 4060%,
• The

of each primer should be matched,

• There should be no complementarity between the primers particularly at the 3’ends,
• Poly-C or G runs towards the 3’-end of primers may cause mispriming at G-i-C
rich regions,
• Primers with significant secondary structures should be avoided and
• Primers should lie within highly conserved regions.

Primers may contain mismatches at the 5’-end for the purpose of introducing
restriction sites or promoter sequences into the amplicons. Software programmes
are available to assist in primer design.

These programs are excellent in

calculating primer T^ values and in predicting the extent (if any) of self
complementarity.

However some of these software programs do not take into

account the primer design guidelines outlined previously.

1.4.3.6

Other reaction components

The recommended buffer for PCR consists of 10-50 mM Tris-HCI [pH 8.3-8.8]. Up
to 50 mM KCI can be included in the reaction mixture to facilitate primer annealing.
Buffers containing ammonium sulphate have also been used (Kogan ^aJ., 1987).
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The cosolvents dimethyl sulfoxide (DMSO) and formamide are included in some
buffers facilitating the amplification of G+C rich regions by promoting strand
separation. However the presence of 10% DMSO inhibits DNA synthesis by 50%
in a 70°C Tag polymerase activity assay (Gelfand

1990; Winship M ai-, 1989).

Gelatin or bovine serum albumin and non-ionic detergents such as Tween-20 are
included to help stabilise the enzyme. For some thermal cyclers (e.g. Pharmacia
LKB Gene ATAQ controller), which do not have heated lids, reaction mix tubes are
overlaid with sterile mineral oil. This step prevents the evaporation of the reaction
components. Other thermal cyclers (e.g. GeneAMP PCR System 9600) where the
lid of the reaction tube is heated continuously (> 96°C) do not require oil overlay

1.4.3.7

DNA template

There are many protocols available for the isolation of nucleic acids. Most methods
aim to isolate highly purified DNA suitable for use in

PCR amplification.

Commercial kits are also available providing standardised, simple and rapid
extraction protocols which

are

particularly

useful

in

molecular

diagnostic

laboratories. The optimum DNA content of a sample for PCR analysis depends on
its purity.

For genetic analysis 100-500 ng DNA is normally required.

For

successful PCR, it is important that the DNA template is free from any potential
inhibitory substance(s). Blood samples may contain reagents like EDTA, heparin,
porphyrins and other related compounds all of which are known inhibitors of PCR.
These compounds need to be removed to permit optimum amplification.

Many

laboratories however have reported successful PCR assays directly on whole
blood or buffy coat samples. One method simply involves microwave irradiation of
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the serum to inactivate PCR inhibitors (Peng et ai., 1996). Other methods involve
preheating an aliquot of blood prior to the addition of the reaction cocktail
(McCusker M ad-, 1992; Rees ^

1996).

This pre-treatment step inactivates

some of the PCR inhibitory factors known to exist in blood.

1.5

Detection of point mutations using modified PCR
methods

The impact of PCR on molecular biology is well recognised.

Its elegance and

simplicity have greatly facilitated the execution of the Human Genome Project (e.g.
provision of rapid DMA sequencing protocols) (Wilson M

1997).

Significant

efforts have also been directed towards the provision of PCR-based mutation
scanning and detection strategies.
In the final sections below scanning methods are described in brief with the
detection protocols as applied to the genetics in more detail.

Mutation detection:

Mutation scanning:

1.SDM-PCR

1. SSCP

2. AS-PCR

2. DGGE

3. ARMS-PCR

3. HD-technology

4. Direct sequencing
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1.5.1
1.5.1.1

Mutation detection
Site-directed mutagenesis (SDM)-PCR

The first molecular strategy used to detect the factor V Leiden mutation was
described by Bertina M ii-, (1994). This method involved the use of the restriction
enzyme Mnll to diagnose the mutated allele after PCR amplification (see Figure
1.12a).

Since Mnll has a four bp recognition sequence (GAGG), nucleotide

substitution in any of these bases would abolish the restriction site giving the same
result as the factor V Leiden mutation alone (Guillerm M

1996).

Furthermore

the Mnll enzyme is expensive and unstable making it unsuitable for large scale
screening.

The latter technical problem has been addressed with the development of
protocols based on site-directed mutagenesis (SDM)-PCR.

Essentially this

involves amplification of the DNA fragment with two primers, one of which is
modified to create a cleavage site in the amplicon only if the mutation is present.
One of the reported methods involves Hind III digestion (see Figure 1.13) after PCR
to detect the G to A mutation responsible for both the abnormal factor V and
prothrombin molecules (Gandrille et

1995b; Poort M aj., 1996).

A multiplex

SDM-PCR strategy was also designed to detect both mutations simultaneously
(see Figure 1.12b). This initially involves amplification of both genes in a one tube
PGR reaction followed by Hind III digestion. This provides a more cost effective
screening method.

SDM-PCR strategies can also be developed to detect

mutations in protein C, protein S and antithrombin III, additional factors involved in
anticoagulation (Maher ^aj., 1998/1999b).
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©
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200 bp-- ^
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37 bp
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Figure 1.12
Schematic representation of two DNA-based methods used to detect factor V Leiden alone (a)
and both the factor V Leiden and prothrombin variants (b).

Each technique requires DNA

extraction using either a commercial kit (QIAamp blood kit, Qiagen, Germany) or by direct analysis
of a small aliquot of blood.

(a) Bertina et

(1994), designed a method which takes advantage of the loss of an Mnll

restriction site in the PCR product (267 bp) in the presence of the G1691A mutation.
Lane 1: Normal PCR amplified fragment; Lane 2: Homozygous for factor V Leiden; Lane 3:
Heterozygous for factor V Leiden.
(b) A duplex method which uses primers that amplify the factor V and prothrombin genes within
the mutation regions taking advantage of SDM-creation of a Hind III restriction site in the amplicons
only if the corresponding mutation is present. Lane 1: Normal PCR amplified fragment for factor V
(241 bp) and prothrombin (345 bp) variants. Lane 2: Homozygous for factor V Leiden (209 bp)
and normal prothrombin variant. Lane 3: Compound heterozygous for factor V Leiden (241 bp +
209 bp) and prothrombin variant (345 bp + 322 bp).
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Normal amplified
factor V fragment

5 '.... GGC GAG CTT TAG AG.... 3 '

I

a)

(b)

Abnormal amplified
Factor V fragment
(G--- ►A)

5'.... GGC AAG CTT TAG A.... 3'

Normal amplified
prothrombin fragment

5'

,AGC GAG CTT CAA T.... 3

I

Hind III

,AGC AAG CTT CAA T.... 3

Abnormal amplified
prothrombin fragment
(G --- ^A)

Figure

Hind III

1.13

Amplification of the factor V gene (a) (Gandrille et al.. 1995) and prothrombin gene (b) (Poort et al.,
1996) within the Gto A mutation site using reverse primers containing mismatches (indicated in
bold).

The PCR-amplified fragment contains a Hind III site (underlined) when nucleotide A is

present (the mutated A is in red).
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1.5.1.2

Allele-specific PCR (AS-PCR)

Polymerase chain reaction with sequence specific primers provides a powerful
technique for the discrimination of alleles resulting from single base substitutions
(Kirschbaum ^af., 1995). Amplification can be performed using a common sense
primer complimentary to both alleles, coupled with two antisense primers, one
complimentary to the normal allele and a second complimentary to the mutated
allele.

Each sample is investigated with two PCR amplifications.

One reaction

mixture targets the wild type whilst the other amplifies the mutated allele. Presence
or absence of a specific PCR product after agarose gel electrophoresis is sufficient
for allele assignment (see Figure 1.14).
G/G

A/A

G/A

Figure 1.14
AS-PCR to detect factor V Leiden.
Two PCR reactions are performed. The “G” reaction contains the common forward primer and reverse
primer complimentary to normal factor V, amplification only occurs when the normal is encoded on the
DNA template.

The “A”

reaction contains the common forward primer and reverse primer

complimentary to abnormal factor V, amplification only occurs with the factor V Leiden allele on the
DNA template.

The normal genotype (G/G) will have a band in the G reaction lane only.

A

homozygous abnormal genotype (A/A) will have a band in the A reaction lane only. A heterozygous
genotype (G/A) will show a band in both reaction lanes.
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Unlike SDM-PCR no post-annplification step is required.

However using this

method for the detection of factor V Leiden occasional inconsistencies in the
reaction were noted (Bellissimo et aj., 1996).

1.5.1.3 Fluorescent-amplification refractory mutation detection systemPCR (F-ARMS-PCR1
ARMS-PCR is similar to AS-PCR except PCR reactions are more specific. These
features are achieved by incorporating a mismatch at the penultimate position of
the anti-sense primers (Newton MaJ., 1989). it was found that a mismatch at the -3
position (i.e. towards the primer 3’-end) is more sensitive and reliable compared to
antisense primers containing a mismatch at the -2 position (Scobie et aj., 1996).
Most traditional ARMS-PCRs like AS-PCR rely on two amplification reactions, one
specific for normal allele and another for the abnormal allele. This limitation can be
overcome by using fluorescently labelled anti-sense primers in a single tube
reaction (Maher MaJ-, in press).

Differential fluorescent dyes are covalently linked to the 5’-end of the anti-sense
primers. The fluorescent amplicons can be detected using GeneScan technology
similar to that for automated DNA sequencing

(e.g. Perkin Elmer Applied

Biosystem, ABI 310, 373 or 377 Genetic Analyzers).

During electrophoresis,

amplicons are excited by an argon laser resulting in an emitted light signal, which
is focused onto a charged couple device (CCD) detector.

The CCD detector

converts the light signal into a voltage signal which the instrument acquires. This
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signal is then transferred to a dedicated connputer containing the necessary
software to process, analyse and store the data.

Presence or absence of a

coloured peak in the GeneScan data trace is sufficient to permit direct and
unambiguous allelic determination.

The essential details of this strategy are

outlined in Figure 1.15.
Factor V Leiden and prothrombin variant have been simultaneously detected using
this method (Maher ^

in press), without the need of post-amplification

procedures. Problems concerning the interpretation of complex gel patterns are
often encountered due to inadequate DNA fragment separation and visualisation
(Bowen et ^., 1998). These difficulties can be overcome using high-resolution
separation techniques such as those based on GeneScan technologies.

Direct Sequencing

The use of direct sequencing as a research tool for detecting mutations is
dramatically growing at a rapid pace.

DNA sequencing has the advantage over

other mutation scanning and detection methods in that it defines both the location
and nature of the mutation. Generally DNA sequencing is used to confirm the
result obtained from the previous methods outlined (as it provides the most
definitive and accurate form of genotyping).

Originally sequencing strategies

required the DNA fragment of interest to be cloned into a suitable vector for
sequencing. However this step proved time consuming, and can be avoided by
direct sequencing of the PCR products. Several methods have been described
(Grompe, 1993; Wilson et ai-. 1997) which are based on either dye-primer or dyeterminator approaches.
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Figure

1.15

Principle of F-ARMS-PCR using the ABI Prism™ 310 genetic analyzer.
(A) Normal homozygote DNA; (B) Heterozygote DNA.

Circles represent the nucleotide of the

normal allele and squares represent the equivalent nucleotide of mutant allele. Open and filled
circles (or squares) are complimentary bases. The reverse primer specific to the normal allele is
labelled with FAM while the reverse primer specific to mutant allele is labelled with HEX.
(A) Only the normal allele is present therefore the FAM-labelled primer (indicated in blue) is
incorporated

into

the

amplicon.

After

capillary

electrophoresis,

the

GeneScanner

electropherogram produces a blue peak.
(B) Both normal and mutant alleles are present both ARMS primers FAM labelled and HEX labelled
(indicated in yellow) produce a PCR product.

Subsequently two peaks (blue and yellow) are

obtained on the GeneScanner electropherogram.
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1.5.2 Mutation Scanning

1.5.2.1

Fluorescence based single-strand conformation polymorphism

(F-SSCP)
SSCP has become a widely used PCR-based technique for mutation detection.
The target sequence is amplified by PCR, denatured and electrophoresed under
non-denaturing conditions usually by polyacrylamide gel electrophoresis (PAGE).
In non-denaturing conditions single-stranded DNA molecules assume unique
conformations that depend on their nucleotide sequences. A change in a single
nucleotide can result in a conformational change that is detected by a mobility shift
in the electrophoresis pattern when compared to the wild type allele (Hayashi,
1992; Gomez ^af., 1997).
The original method as described by Orita et
as the signal generator for mutation detection.

1989 made use of radioisotopes
Since the first methods emerged,

several groups have begun to use non-isotopic detection methods. One example
of this is the use of fluorescently labelled primers (see Figure 1.16), in which the
amplicons can be detected using an automated DNA sequencer (Makino ^ ^.,
1992; Boutin et ai., 1997) after amplification.

This permits the use of an internal

size standard allowing the user to carefully monitor for even minor mobility shifts
and thereby enhancing the sensitivity of mutation detection. Differential labelling of
the two DNA strands allows easier interpretation of the results. However there are
limitations to SSCP whether isotopic or non-isotopic detection methods are used.
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PCR

PCR

mutant

wildtype
A

Denature

A
single strand
conformation depends
on sequence

Run on non-denaturing
Geriescan polymer

Figure

1.16

The ABI Prism 310 PCR-SSCP technique. The fluorescent strands of mutant template migrate in
a different pattern in comparison to wildtype template.
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These include:
• Subsequent DNA sequencing must be performed to determine the nature and
exact location of any mutation(s).
• SSCP detects only 70-95% of mutations in PCR products of 200 bp or less
(Grompe, 1993). The sensitivity of the method decreases as the size of the PCR
product increases.

1.5.2.2

Denaturing gradient gel electrophoresis (DGGE)

DGGE allows the separation of DNA molecules differing by a single base change.
Double

stranded

DNA

obtained

by

PCR

is

electrophoresed

through

a

polyacrylamide gel containing an increasing concentration gradient of denaturant
concentration (eg: urea and formamide) (Myers M a]., 1987; Grompe, 1993; Carter
et aj., 1995).

As the DNA migrates it enters the denaturing gradient where its

lowest melting temperature domain causes the part of the molecule to form a
branched structure that has a retarded mobility.

DNA molecules differing by one

nucleotide may alter DNA melting properties and can be detected as changes in
the electrophoretic mobility (Path ^

1998). To increase the sensitivity of this

technique a GC clamp can be attached to the 5’-end of one primer (see Figure
1.17), this ensures that the amplified sequence has a low dissociation temperature.
DGGE detects approximately 95% of mutations in PCR products of up to 600 bp in
length.

As with SSCP, the nature of the mutation must be defined by DNA

sequencing at a later stage.

56

5

’

5

’

GC clamp

40 bp

c

g
ca
k—

O)
0

Direction of
migration

E
03
E
o
0
13

Figure 1.17

PGR product with a GC clamp of 40-45 nucleotides is produced after amplification with one of the
primers creating an additional GC rich-domain. The amplicons are electrophoresed by DGGE.
Fragment migration is dependent on the thermal dynamics of each domain (which in turn is
sequence dependent). Lane 1: Normal DNA; Lane 2 and 3: Mutant DNA.
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1.5.2.3

Heteroduplex Technology

This method involves the hybridisation of the PCR product with a heteroduplex
generator (HG). The HG is a DNA molecule possessing a specified deletion in the
area of the mutation (Nagamine et a]., 1989).

Heteroduplexes result from the

mixed hybridisation and a molecule with a single nucleotide change will show
differential mobility from a wildtype heteroduplex after electrophoresis on a
standard PAG.

Recently new gel matrices (Hydrolink® and MDE™ from AT

Biochem) have become available which increase the sensitivity of detection. If the
PCR products were fluorescently labelled then the heteroduplexes may be
detected by automated DNA sequencers. Recently Bowen Mai-, (1998) developed
a multiplex heteroduplex technique to detect factor V Leiden, the prothrombin
variant

and

the

methylenetetrahydrofolate

reductase

(MTHFR)

variant

simultaneously.
It is estimated that this technique can detect greater than 95% of mutations in small
DNA fragments (< 300 bp). Heteroduplex technology is an attractive technique as
it only involves a single PCR for each sample and is followed by direct product
analysis.
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Objectives

Resistance to activated protein C (APCr) is now recognised as the most prevalent
risk factor of venous thrombosis, associated with 20-65% of thrombotic cases. The
mutation within the factor V gene, factor V Leiden, is present in 90-95% of ARC
resistant cases. With such prevalence there is need for sensitive, specific, time
saving and cost-effective assays for detection.
The main objectives of this study were:
(i) Analysis of 40 thrombotic patients using two coagulation-based assays; an
activated partial thromboplastin time (aPTT) assay and a protein C activator (PCA)based assay. The sensitivity and specificity of these methods were determined and
compared to the genotyping data.

(ii) Development of a double fluorescent amplification refractory mutation detection
system (dF-ARMS)-PCR technique for simultaneous detection of factor V Leiden
G1691A and the prothrombin G20210A mutations.

Phenotyping and genotyping of 75 thrombotic patients presented for cardiac
venografting. Thrombotic tendencies were analysed phenotypically using TEG.
Subsequently these patients were further analysed through SDM-PCR protocols
for factor V Leiden, prothrombin variant and for mutations within protein C and
antithrombin III.
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Chapter 2
Materials and Methods

This section has been presented as two parts.

Section 2.1 outlines all of the

chemicals, reagents, buffers and other items of equipment necessary for the
experimental work described. All experimental methods are described in detail in
Section 2.2.

2.1 Materials

2.1.1

Blood samples

Blood samples were obtained from two sources.
Two groups of patients attended anticoagulant monitoring clinics.

They were

receiving anticoagulant therapy because of a previous thrombotic episode
associated with normal protein C, S and antithrombin III.
The third group of patients were attending Harefield Hospital, Middlesex and were
undergoing cardiac venografting.
Blood samples were obtained by venipuncture and collected in EDTA or trisodium
citrate treated tubes (Gandrille et aj., 1995b).

2.1.2

Control DNA samples

Factor V Leiden homozygous and heterozygous DNA samples were kindly
supplied by Prof. Dahiback (Lund University, Malmc, Sweden).
A heterozygous prothrombin variant DNA sample was supplied by Dr. Poort
(Haemostasis and Thrombosis Research Center, Leiden, The Netherlands).
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2.1.3 DNA extraction from whole blood
DNA was extracted and purified from a buffy coat of each blood sample using the
QIAamp Blood kit (Qiagen Ltd., West Sussex, UK). This kit contains spin columns,
2 ml collection tubes, kit reagents designated AL1 and AL2, buffers AW and AE and
Qiagen protease.

Distilled water must be added to the lyophilised Qiagen

protease, aliquoted and stored at -20°C. Buffer AL was prepared by adding all of
reagent AL1 to reagent AL2 and this mixture was then stored in the dark at room
temperature.

Ethanol (96-100%) must be added to buffer AW before use.

(Essentially the kit was maintained and used according to the manufacturers
instructions).

2.1.4

Site-directed mutagenesis (SDM)-PCR

2.1.4.1 Reagents for SDM-PCR

Tag DNA polymerase:
Tag DNA polymerase (5U/|il) was obtained from Promega (Promega, Madison, Wl).

dNTP mix:
Deoxyribonucleotide triphosphates (dATP, dCTP, dGTP, dTTP) were supplied by
Promega (Promega, Madison, Wl) at a concentration of 100 mM each. A working
dNTP mix was prepared by adding 2.5 ul of each dNTP in 190 ul of sterile distilled
water, resulting in a final concentration of 1.2 mM for each dNTP. The stock dNTPs
and working dNTP mix was stored at -20°C.
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Gitschier PCR buffer:
A 10X Gitschier PCR buffer contained 540 mM Tris-HCI (pH 8.8), 54 mM MgCl2, 54
pM EDTA and 133 mM (NH4)2S04 (Bertina et al., 1994). This buffer was aliquoted
into 1.5 ml sterile eppendorfs and stored at -20°C.

DMSO:
Dimethyl sulphoxide was obtained from Sigma (Sigma, Poole, UK).

BSA:
Bovine serum albumin was obtained from Sigma (Sigma, Poole, UK). A working
stock of 4 mg/ml was prepared. For simplicity this was designated 10X, and this
notation is used throughout this work. Aliqouts of 10X BSA stock were stored at 20°C.

p-Mercaptoethanol:
P-Mercaptoethanol was supplied by BDH Chemicals Ltd. (BDH Chemicals Ltd.,
Poole, UK).

A 25X working stock with a final concentration of 200 mM was

prepared in sterile distilled water This was stored in the dark at room temperature.
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2.1.4.2 SDM-PCR primers
The blood samples from all patients were investigated using primers (forward and
reverse) directed at both the factor V and prothrombin genes.
The Harefield Hospital blood samples were investigated for addtional mutations in
the protein C gene (A to G mutation within the TATA box at nucleotide position 1533; C to T mutation within exon 9 at nucleotide position 8403) and the
antithrombin ill gene (G to T mutation within the reactive site at nucleotide position
13268). All primer characteristics together with other relevant details are given in
Table 2.1. These oligonucleotide primers were synthesised, purified by HPLC and
supplied in lyophilised form by Eurogentec (Eurogentec, Abingdon, UK).
The concentration of these primers was calculated as follows:

quantity in pg

concentration of primer (pmol/ml) =

molecular weight of primer

A working stock of 10 pmol/pl was prepared for each primer and this stock was
aliquoted in small volumes and stored at -20°C.

2.1.4.3 PCR purification
All PCR products for restriction digestion were purified using a QIAquick PCR
purification kit (Qiagen Ltd., West Sussex, UK). This kit contained QIAquick spin
columns, 2 ml collection tubes, and kit buffers PB and PE. Ethanol (96-100%) must
be added to buffer PE prior to use.
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2.1.4.4 Restriction digestion
To determine if an amplicon contains a polymorphic nucleotide mutation, restriction
enzyme analysis was used.

The following enzymes were supplied with the

appropriate buffers from Boehringer Mannheim (Boehringer Mannheim, Germany).
They were all stored at -20°C.

Enzyme

Recognition
Sequence

SuRE/Cut™

Volume activity

Buffer

(units/pl)

Hind III

AiAGCTT

B

10

Kpn 1

GGTACiC

L

10

Bgll

A i GATCT

M

10

Dra 1

TTTiAAA

M

10

2.1.5

Agarose gel electrophoresis

2.1.5.1 Agarose types
Agarose ultra pure electrophoresis grade was obtained from Life Technologies Inc.
(Life Technologies Inc., Rockville). Low melting point agarose, preparative grade
for small fragments was obtained from Promega (Promega, Madison, Wl).

2.1.5.2 Ethidium bromide
A working stock of 10 mg/ml was prepared in distilled HpO and was stored in the
dark at room temperature.

Ethidium bromide (EtBr) was obtained from Sigma

(Sigma, Poole, UK).
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2.1.5.3 Electrophoresis buffers
- 10X Tris-Acetate-EDTA (TAE) buffer, [pH 7.8] contained 400 mM Tris, 400 mM
glacial acetic acid and 20 mM EDTA.
- 10X Tris-borate-EDTA (TBE) buffer, [pH 8.3] contained 900 mM Tris, 900 mM
boric acid and 25 mM EDTA.
- 10X loading buffer contained 6.6 ml glycerol, 3.3 ml 10X TBE and 100 jil of 10%
(w/v) bromophenol blue.

2.1.5.4 Molecular weight markers
Grade V molecular weight markers were obtained from Boehringer Mannheim
(Boehringer Mannheim, Germany). The 22 DMA fragments in this marker range in
length from 8-587 bp. These were generated by digesting pBR322 to completion
with Hae III. (see Appendix 1 for relative sizes of each marker).

2.1.6

GeneScan analysis

2.1.6.1 Reagents for fluorescent TFI-ARMS-PCR
.All reagents (with the exception of the primers)used in this experimental design
were the same as those previously outlined for SDM-PCR (see Section 2.1.4.1).
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2.1.6.2 F-ARMS-PCR primers
One group of patients from the anticoagulant monitoring clinic were investigated
using dye-labelled primers directed at both the factor V and prothrombin genes. All
primer characteristics together with relevant details are given in Table 2.2.
Oligonucleotide primers for the F-ARMS-PCR were synthesised and purified by
Applied Biosystems (Perkin-Elmer, Applied Biosystems, Warrington, UK).

2.1.6.3 Applied Biosvstems (ABh Prism™ 310 genetic analyzer reagents
Note: All reagents for GeneScan analysiswere supplied by Perkin-Elmer (PE)
Applied Biosystems (PE-Applied Biosystems,Warrington, UK).

(a) 310 Genetic analyzer buffer with EDTA (lOX):
• Working IX genetic analyzer buffer was made up as follows:
- 2 ml 10 X genetic analyzer buffer
- 18 ml HPLC water

(b) GeneScan™ polymer:
2.5% GeneScan™ polymer was made up by combining the following:
- 0.35 g GeneScan™ polymer
100 pi 10 X genetic analyzer buffer
- 550 pi HPLC water
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2.1.6.4 GeneScan molecular weight standards
GeneScan™ 500-TAMRA standards consist of dye-labelled DNA fragments from
35 to 500 bp in size. All are single-stranded size standards labelled with a TAMRA
NHS-ester dye (see Appendix 2 for relative sizes of this standard).

2.1.7

Direct Sequencing

2.1.7.1 Reagents for cycle sequencing
ABI prism™ Dye Terminator cycle sequencing reaction kit was supplied by PE
Applied Biosystems (Warrington, UK).

It contains -21 Ml3 (forward) primer and

pGEM®-32f (+) double stranded template for control reactions.
The terminator premix consisted of the following;
A-dye terminator, C-dye terminator, G-dye terminator, T-dye terminator, dITP, dCTP,
dTTP, dATP, Tris-HCI (pH 9.0), MgCl2, thermo stable pyrophosphatase and
AmpliTaq FS DNA polymerase.

2.1.7.2 Extension product purification
-vSodium actetate supplied by BDH Ltd., (BDH Ltd,, Poole, UK). A 3 M stock (pH
4.6) was made up and stored at room temperature.
-Ethanol (95% and 70%).

2.1.7.3 DNA sequencing reagents
-Template Suppression reagent
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-DNA sequencing polymer (3 ml syringe)
The above reagents were obtained from PE Applied Biosystems (Warrington, UK)
and were stored at 4°C.

2.2 Methods

2.2.1

DNA extraction from blood

2.2.1.1 Preparation of buffy coat
Buffy coat was prepared from whole blood by centrifugation at 2000 rpm at room
temperature for 10 minutes.

After centrifugation, three different fractions were

obtained. The upper clear layer was plasma, the intermediate layer was the buffy
coat containing leukocytes and the bottom layer contained erythrocytes.

The

intermediate layer was removed and stored in sterile eppendorfs at -20°C prior to
use.

2.2.1.2 QIAamp blood extraction protocol
The QIAamp blood kit (Qiagen Ltd., West Sussex, UK) was used to purify total DNA
from the buffy coat. This kit can be used on samples which have been treated with
citrate, heparin or EDTA and samples may be processed when either frozen or
fresh. The protocol outlined by the manufacturers was as follows:
• To 200 pi of buffy coat, 25 pi of Qiagen protease and 200 pi of buffer AL were
added. The sample was vortexed for 15 sec to dissolve any pellets.
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• The sample was then incubated at 70°C for 10 minutes to lyse the cell.
Following the latter step, 210 pi of ethanol (96-100%) was added and the
sample was placed into a QIAamp spin column that was attached to a collection
tube.
• A brief centrifugation at 8000 rpm for 1 minute was performed. DNA binds to the
silica gel membrane of the spin columns.
• The spin column was washed twice with 500 pi of buffer AW and the DNA was
eluted with 200 pi of preheated water (60^C).
Finally the DNA yield was determined by measuring the absorbance at 260 nm of
DNA in the eluate to determine its concentration.

The purity of the DNA was

determined by obtaining an absorbance at 260 nm and 280 nm. Pure DNA has an
^260/280

2.2.2

1.7-1.9.

SDM-PCR

2.2.2.1 Amplification process
Amplification reactions were performed in a final volume of 50 pi in thin walled
tubes consisting of 500 ng genomic DNA template, 5 pi of Gitschier buffer, 300 pM
of each dNTP, 8% DMSO, 2 pi of 25X p-mercaptoethanol, 5 pi of 10X BSA, 30
pmole(s) of each primer (Table 2.1) and 2 U of Tag DNA polymerase. All samples
were amplified in a PTC-150 minicycler (MJ Research Inc., Watertown, MA). The
lid of the reaction tubes are heated continuously to > 96°C in this thermal cycler.
The cycling profile used for the amplification was as follows:
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1 cycle

94 °C for 5 minutes
94 °C for 1 minute
*58 °C for 1 minute

30 cycles

72 °C for 1 minute
72 °C for 7 minute

1 cycle

4°C

Hold

* For protein C exon 9 amplification the annealing temperature was increased to
64°C and for protein C TATA amplification the annealing temperature was adjusted
to 60 °C (see Table 2.1).
The amplicons generated during PCR amplification were analysed in a 1.5%
agarose gel.

2.2.2.2 Agarose gel electrophoresis
Electrophoresis was performed in either a Horizon® 58 or 11.14 horizontal gel
apparatus from Life Technologies Rockville, USA, for 1-2 hours at 90V. Two types
of agarose gels were used depending on the resolution required.
(a) A 1.5% agarose gel solubilized in IX TAE containing 35 ng/ml EtBr, and
(b) A 2% low melting point (LMP) agarose gel (Promega, Madison, Wl) solubilized
in IX TAE containing 35 ng/ml EtBr.

All ethidium bromide stained gels were visualised
transilluminator.

on an ultraviolet (UV)

The results were analysed and stored using the GRAB-IT'^
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software of UVPs Gel Documentation and Analysis system-GDS8000 (Ultra-Violet
Products Ltd., Cambridge, UK).

2.2.2.3 PCR product purification
The PCR products obtained after SDM-PCR must be purified prior to restriction
enzyme digestion.

The QIAamp PCR purification kit (Qiagen Ltd., West Sussex,

UK) was used for this purpose. This kit rapidly purifies the double stranded DNA
from primers, excess nucleotides,

polymerases

and

salts.

The

protocol

recommended by the manufacturers was followed:
• Five volumes of buffer PB were added to one volume of PCR product and the
mixture was applied to a QIAquick spin column which was attached to a
collection tube.
• The sample was centrifuged at 8000 rpm for 30-60 seconds to bind the DNA to
the silica gel membrane of the column.
• DNA was washed with 0.75 ml of buffer PE yja centrifugation, (as above).
• The QIAquick column was then placed in a sterile eppendorf and the DNA was
eluted with 30 pi of preheated sterile water (60°C).
This purified PCR product can subsequently be used for restriction digestion.

2.2.2.4 Restriction enzyme analysis
The presence of a mutation in an amplicon after SDM-PCR can be determined
simply by restriction enzyme analysis. A restriction site will only be created if the
73

mutation is present. The type of enzyme used depended on the PCR product.
Table 2.1 indicates which enzyme should be used for each amplicon.
Generally, the following digestion protocol was followed:

PCR purified product

22.5 |il

10X buffer

2.5 pi

Restriction enzyme

1 pi

* A control digest was also prepared for each enzyme using 2 pi of lambda DNA.
The total volume was made up to 25 pi with distilled H2O. All tubes were placed at
37 °C for 1.5 hours.

Samples were analysed by electrophoresis in a 2 % LMP

agarose gel.

2.2.3

GeneScan analysis

2.2.3.1 Fluorescent-ARMS-PCR
This protocol was designed to detect the factor V Leiden and prothrombin variant
simultaneously.

Genotypes were determined in a single tube PCR reaction

consisting of a forward primer which was unlabelled together with two differentially
labelled antisense primers. All primer characteristics are given in Table 2.2.
Amplification reactions were performed in a final volume of 50 pi consisting of 500
ng genomic DNA template, the same buffer, dNTP, DMSO and p-Mercaptoethanol
concentrations as previously outlined (see Section 2.2.2.1). The reaction mixture
was overlaid with paraffin oil and together with 15 pmoles of each primer (see
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Table 2.2) and 2 U of Tag DNA polymerase, amplification was carried out in a
Pharmacia LKB Gene ATAQ Controller (Pharmacia, Uppsala, Sweden).

The

following amplification profile was used:

94 °C for 5 minutes

1 cycle

94 °C for 1 minute
58 °C for 1 minute

30 cycles

72 °C for 1 minute
72 °C for 7 minute

1 cycle

4°C

Hold

2.2.3.2 F-PCR product purification
F-PCR products were purified prior to GeneScan analysis.

The QIAamp

purification kit (Qiagen Ltd., West Sussex, UK) was used for this purpose.

(See

section 2.2.2.3).

2.2.3.3 GeneScan analysis
The ABI Prism™ 310 Genetic Analyzer has the ability of determining the size and
quantity of F-labelled DNA fragments (see Figure 2.1).

Once the samples are

loaded they are electrophoresed through a polymer filled capillary. The fluorescent
dyes attached to the DNA fragments are excited by the iaser and emit iight at a
specific wavelength. This light is “grabbed” by the detector which transfers it to the
data collection program. Finally these signals are eventually
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, Capillary

Syringe drive
Syringe
Gel Pump button

Heat plate

\

Heater door

Tray button

Buffer reservoir

/

y // -

/
"" /
/ Pump block
LED Status indicators

' /

j

I
^

/

~

^
i

L—i_Qser detector door

(covers detector
window)

\'

Cathode electrode

\

\
Autosampler

Figure 2.1
ABI Prism™ 310 Genetic Analyzer.

Syringe guide plate

2.5-mL glass syringe

Pump block

Figure 2.2
Set up for GeneScan analysis. Note the position of the 2.5 mi glass syringe.
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processed by the system software (ABI Prism™ 310 GeneScan™ analysis 2.0.0).

Setting up the instrument for GeneScan analysis
Initially the pump block is washed with warm water and then HPLC water to remove
any residual polymer and/or urea. The 2.5 ml high pressure glass syringe is then
filled with 2.5 % GeneScan polymer, and screwed tightly into the gel block (see
Figure 2.2). The buffer reservoir was filled to the red line with IX genetic analyzer
buffer. This buffer was also placed at position 1 of the autosampler tray and HPLC
water was placed at positions 2 and 3. A GeneScan capillary (46 cm) is then
installed into the instrument.

Filling the pump with gel manually
The ‘buffer valve close’ command was chosen from the manual control window,
the valve above the waste vial was opened and the channel to the waste was filled
with polymer by pushing down on the glass syringe.
was then closed.

Once completed the valve

The buffer valve was opened and the channel to the buffer

reservoir was also filled with polymer.

Once complete, the syringe toggle was

moved to the right and then moved down until the toggle was 1-2 mm from the
glass syringe plunger.
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Preparing the sample
For GeneScan analysis each sample was prepared in a 0.5 ml genetic analyzer
sample tube as follows:
1 |il PCR purified F-labelled product
0.5 |il GeneScan™ 500-TAMRA
48 pi HPLC water
The tube was subsequently covered with a genetic analyzer septum.

Loading and running the ABI Prism™ 310 Genetic Analyzer
The sample tubes were placed in the autosample tray beginning at position A1, A3
etc. A GeneScan sample sheet for a 48 well sample tray was created by recording
the sample names in the appropriate column.

In the standard column the blue,

yellow and red boxes were ticked (see Figure 2.3). Blue represents FAM-label,
yellow represents HEX-label and red represents TAMRA-standard.

The sample

sheet associates sample information with a sample tube position.
Subsequently an injection list is created. This specifies the order in which each
sample will run and the type of module and running conditions used for each
injection.

First, the sample sheet Is imported into the injection list.

module window the specific module was chosen.

From the

The modules used for

GeneScan analysis were PushFill modules (A or C depending on which virtual
filter to be used). With these modules the samples are electroinjected into the
capillary for 10 sec and electrophoresed for 20 minutes at 11 kV at 30°C through
the 2.5 % GeneScan polymer.
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Sample Sheet “Sample Sheet-Q/^/QS 10.16”
GeneScan^ Sample Sheet

*

A3

Sample Name

Color Std

Pres

negative

mpm\

El

1

V

1

El
El
El

1

V

1

factor V -het

Sample Info

Comments

□
□

A5

Factor ll-het

IZZl

llViVl
1

1

iryni
[S
A7

Factor V normal

El
El
El

□
E

IlgBM

E
E

1
.1

E
E

1
f

V

'ii

□

Figure 2.3

A GeneScan sample sheet.

2.2.4

Direct sequencing

The ABI Prism™ 310 Genetic Analyzer (Applied Biosystems, Foster City, CA) is
an automated instrument capable of determining the base sequence of dye
terminator DNA products.

As the product is electrophoresed through the

capillary, the fluorescent labelled nucleotides are excited by the argon laser and
emit light at a specific wavelength.

The transmitted light is collected by the

detector which relays the information to the data collection software (ABI
Prism™ 310 DNA sequencing software 2.1.2) of dedicated Apple Macintosh
Power PC. The sequence analysis software subsequently analyzes the data
collected by the data collection program. This technique was used to validate
SDM-PCR protocols. It was performed on normal, factor V Leiden heterozygous
and homozygous samples and on normal and prothrombin heterozygous
samples.
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2.2.4.1 Cycle sequencing
Initially the region containing the mutations in the factor V and prothrombin genes
from the above samples were amplified via SDM-PCR. These fresh PCR products
were purified using the QIAamp PCR purification kit (as outlined in Section 2.2.2.3).
The

DNA

concentration

of

each

PCR

product

was

determined

spectrophotometrically and diluted to a final concentration of 30 ng/pl with distilled
HgO.

Next a subsequent amplification reaction was performed on the PCR

products to produce a new amplicon in which the nucleotides (A/G/C and T) are
differentially labelled.

This amplification reaction was performed in a 0.5 ml

microcentrifuge tubes in a final volume of 20 pi consisting of 4pl of PCR product,
8pl of terminator ready reaction mix and 3.2 pmol of primer (forward or reverse).
These primers are the SDM-PCR primers used previously (see Table 2.1). Both
forward and reverse cycle sequencing reactions were performed on each sample.
The reaction mixture was overlaid with 40 pi of parrifin oil and amplification was
carried out in a Pharmacia LKB Gene ATAQ Controller (Pharmacia, Uppsala,
Sweden). The following amplification profile was used:
96 °C for 30 seconds
50 °C for 15 seconds
60 °C for 4 minute

25 cycles

4°C

Hold

2.2.4.2 Extension product purification
Excess dye terminators were removed from the samples before sequencing by
ethanol precipitation. The following protocol was used:
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Initially 2.0 ^il of 3 M sodium acetate (pH 4.6) was mixed with 50 pi of 95%
ethanol in a 1.5 ml microcentrifuge tube.
The cycle sequencing reaction mixture was added to the ethanol solution. The
tubes were vortexed and left on ice for 10 minutes.
The samples were centrifuged at 12 000 rpm for 30 minutes.
The ethanol was carefully removed and the resulting pellet was washed with
250 pi of 70% ethanol.
All traces of alcohol were removed and the pellet was left to dry.

2.2.4.3 Setting up the ABI Prism™ 310 analyzer for sequencing
Initially before a sequence run any residual polymer or urea must be removed from
the pump block by washing in warm water and then in HPLC water. A 0.25 ml high
pressure sequencing syringe is screwed tightly onto the pump block (see Figure
2.4) and a sequencing capillary (47 cm) was installed. The buffer reservoir was
filled to the red line with IX genetic analyzer buffer. These steps were similar to
those outlined for GeneScan analysis (see section 2.2.3.3).

2.2.4.4 Filling the pump with gel manually
A full syringe of sequencing gel polymer (equilibrated to room temperature) was
attached to the plastic syringe luer valve (see Figure 2.4). The “buffer valve open”
command was selected from the manual control window. The channel to
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Syringe drive toggle

Syringe guide

— 250-\iL glass sequencing syringe
Buffer reservoir valve
Plastic syringe luer valve

Waste valve
Buffer reservoir

Waste vial

Figure 2.4
Instrument set up for sequence analysis on an ABI Prism™ 310 Genetic analyzer. Note the
positions of the plastic syringe and 250 pi glass sequencing syringe.
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the buffer resevoir was filled with sequencing polymer by pushing down on the
plunger of the plastic syringe. The buffer valve was closed and the valve above
the waste vial was opened. The channel to the waste was similarly filled with
sequencing polymer. Once complete this valve was closed.

The glass syringe was filled with 50 jil of sequencing polymer by pushing down
on the plunger of the plastic syringe. The waste valve was opened and the
plunger of the glass syringe was pushed. These latter two steps were repeated
until the glass syringe was free of air bubbles. The glass syringe was filled with
sequencing polymer to 100 pi.

This amount depended on the number of

sequencing samples. The syringe drive toggle was moved to the right and then
moved down until the toggle was 1-2 mm from the end of the glass syringe.
The plastic syringe filled with sequencing polymer was removed, capped and
stored at 4°C. Another plastic syringe filled with water was attached to the luer
fitting. Genetic analyzer buffer (IX) was placed in position 1 of the autosampler
tray and HPLC water was placed in positions 2 and 3.

2.2.4.5 Filling the capillary with sequencing gel
A small tube containing 0.5 ml water was placed in position 6 of the
autosampler tray. The sequence fill capillary function was selected from the
manual control screen and the run was initiated. The instrument begins to fill
the capillary with the polymer. This module will also detect any leaks coming
from the glass syringe.
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2.2.4.6 Preparing the sample
To the now dried DNA sequencing reaction (see Section 2.2.4.2), 25 [l\ of
Template Suppression reagent was added.
denatured at 95°C for 2 minutes.

This was mixed thoroughly and

Subsequently it was chilled on ice.

The

sample was transferred to a 0.5 ml genetic analyzer tube and covered with a
septum.

2.2.4.7

Loading and running the ABI Prism™ 310 Genetic Analyzer for

sequencing
Sample tubes were placed in the autosampler tray, beginning at position A1, A3
etc. A sequence sample sheet was created by recording the sample names in
the appropriate column. This associates sample information (name and type of
analysis) with a sample position. Following this an injection list was prepared
(see Figure 2.5) which describes the number of injections, which sample was
used and the type of module and running conditions used for each injection.
The appropriate sample sheet was imported into the injection list window which
automatically becomes filled with information from the selected sample sheet.
In the module pop-up menu, Seq run A was chosen and once selected the
running parameters were filled in automiatically. Once complete the sequence
run was initialised.
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Figure 2.5
An ABI Prism™ 310 genetic analyzer sequence injection list.

2.2.4.8 Analysis of sequence data
The ABI Prism™ 310 Genetic Analyzer contains sequencing analysis software
which permits analysis of DNA sequence data. All results were stored on a
dedicated Apple Macintosh Power PC computer linked to the system. Initially
the software processes the data, then it detects the peaks and determines the
sequence.

It has an accuracy of 98.5% to 425 bases.

Sequencher™ 3.0

software (Gene Codes Corporation Inc., Ann Arbor, Ml) was used to further
analyze the processed data.

Sequences can be edited to remove vector

sequence and any ambiguous bases (N) in the sequence can be corrected by
overviewing the related chromatogram. The package also allows the user to
locate specific restriction enzyme recognition sites within the sequence.
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Abstract
The number of requests for molecular diagnosis of factor V Leiden received by the
Molecular Diagnostics Unit (MDU) based at Cork Institute of Technology (CIT)
greatly increased recently. This observation prompted us to re-evaluate current
diagnostic methods and assess the need for subsequent DNA-based investigation.
Since the prevalence of activated protein C resistance (APCr) and its association
with deep vein thrombosis (DVT) is well recognised provision of a cheap, sensitive
and rapid diagnostic assay is required. Several coagulation-based protocols are
now commercially available.

Performance characteristics differed in some assay

designs and this feature may require additional investigation using specific genetic
tests in order to obtain an accurate diagnosis.

This may be at least one of the

reasons which led to increased demand(s) for determination of factor V Leiden
genotype.
In this study we analysed forty DVT patients and forty normal controls for APCr
using two coagulation-based assays; an activated partial thromboplastin time
(aPTT)-assay and a protein C activator (PCA)-based assay.

To improve the

specificity of these tests, a predilution of test plasma in factor V-deficient plasma
was carried out prior to analysis. We subsequently genotyped the study population
using a site-directed mutagenesis polymerase chain reaction (SDM-PCR) protocol.

(Key words: activated protein C resistance [.APCr]; factor V Leiden; coagulationbased assays; SDM-PCR).
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Introduction
Venous thrombosis is a serious health problem, affecting approximately 1 in 1000
individuals annually.

Mutations in genes encoding the blood clotting pathway

components play an important role in the predisposition to venous thrombosis.
Inherited deficiencies of the anticoagulant factors protein C, S and antithrombin are
recognised in fewer than 5-10% of affected patients.^’^

Activated protein C resistance (APCr) was first described in 1993 by Dahiback et
al.^ Substitution experiments implicated factor V as the underlying cause of APCr.
Genome analysis demonstrated that a G to A transition at nucleotide position 1691
in the factor V gene was responsible for 90-95% of activated protein C resistant
cases.

This mutation produces an abnormal factor V molecule, factor V Leiden,

wherein Arg

[CGA] was substituted by Gin [CAA] resulting in partial resistance to

proteolytic inactivation by activated protein C.

Activated protein C resistance is

now recognised as the most prevalent coagulation abnormality associated with
venous thrombosis occurring in an estimated 20 to 65% of familial thrombotic
cases

5. 8. 9

The APCr phenotype was originally determined using a coagulation assay based
on the standard aPTT (activated partial thromboplastin time) test. ^ This laboratory
test relies on the determination of two aPTTs, one performed in the presence of
exogenously added APC and the other in its absence. The relationship between
the two aPTT values is then expressed as a ratio, the APC ratio. These assays are
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simple to perform, inexpensive and can be easily automated. As an initial screen
for APCr, such assay characteristics ensure a cost effective test delivery. Several
modifications to the original test such as prediluting test plasma with factor Vsubstrate plasma, have been reported extending analysis to those patients on oral
anticoagulants and/or heparin.

However in some cases there is an overlap

between the APCr ratios from normal individuals and those heterozygous for factor
V Leiden resulting in an diagnostic sensitivity and specificity of less than 100%.^
Furthermore this simple test may also be influenced by instrumentation, reagents,
sample preparation and handling.

Definitive confirmation of APCr requires an

individual’s DNA to be genotyped.

Novel molecular strategies have been designed to detect the factor V Leiden allele.
The first reported method was described by Bertina et al.

and involved the

use of the restriction enzyme Mnl I to diagnose the affected allele after polymerase
chain reaction (PCR) amplification.

Since then many improved PCR-based

methods have been designed to specifically detect the mutation.

One such

strategy involves the use of site-directed mutagenesis (SDM)-PCR wherein the
reverse primer contains a mismatch creating a restriction site in the amplicon only if
the mutation is present, which is subsequently detected by digestion.
Genetic testing has the advantage of being independent of pathology, ongoing
therapy and preclinical conditions.

Genotyping provides a definitive result,

confirmatory testing is not necessary.
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In this report we analysed forty DVT patients undergoing warfarin treatment and
forty normal controls [drawn at random from a College population from whom
written consent was obtained], using phenotypic and genetic methods.

We

compared the performance of two coagulation assays, a modified aPTT test and
the protein C activator (PCA)-based assay to detect factor V Leiden carriers. These
data were then compared to results from genotyping experiments based on an
SDM-PCR

protocol.
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Materials and Methods
Patients and controls
Forty DVT patients attending anticoagulation monitoring clinics and forty normal
controls were included for this study.

The former patient group were receiving

warfarin therapy because of a previous thrombotic episode and the normal
subjects were drawn at random (from a College population) none of whom had any
history of thrombosis. The age range of the DVT patients was 29 to 87 years
(median age of 68 years) of whom 19 were females and 21 were males.

All

subjects studied were of Caucasian origin.

Blood collection and sample preparation
Venous blood was drawn from the antecubital vein into evacuated tubes containing
0.1

mol/L sodium citrate.

Platelet-poor plasma (PPP)

was

obtained

by

centrifugation at 2000 g for 20 min at room temperature and immediately stored at
-70°C until use.

Buffy coats were also obtained and stored at -70°C prior to

genomic DNA purification.

Assays to detect APC resistance
The assays for anticoagulant response to APC were performed using two methods,
a) Modified aPTT-based APCr assay. Plasma from all participants was assayed in
duplicate using the Coatest APC Resistance Kit (Chromogenix, Moindal, Sweden),
following the manufacturer’s instructions. Results were expressed as a ratio (APC
ratio) between aPTT in the presence of an added normalised amount of APC and
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aPTT in the absence of added APC. A student t-test was applied to compare the
APC ratios between the nornal control group and the affected group.

The

frequency of ACPr was found not to differ significantly between normal individuals
and DVT patients (p=0.057).

b) PCA-based APCr assay. All plasmas were assayed in duplicate with a Diagen

PCA Kit from Diagnostic Reagents Ltd. (Oxon, UK), following the manufacturer’s
instructions. This assay requires the addition of a PCA obtained from the venom
fractions of Agkistrodon contortrix, thus it is unnecessary to use preformed APC to
detect APCr. Results were again expressed as a ratio (PCA ratio) between aPTT in
the presence of PCA and in its absence. Similarly as for a) above a student t-test
showed that in this case there was a statistically significant (p=0.0004) trend
towards higher occurance of APCr in the affected group compared to normal
controls.

Both methods (outlined in a and b above), were performed on patient plasma
previously diluted 1/5 with factor V-substrate plasma. Clot formation was measured
in a SYSMEX CA-6000 analyser (SYSMEX, Long Grove, IL).

Extraction of genomic DNA
Total genomic DNA was recovered from the frozen leukocytes using a QIAamp
Blood Kit (Qiagen Ltd., West Sussex, UK). Briefly, following buffy coat isolation.
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200 }iL were lysed in a chaotropic lysis buffer (provided in the kit) and applied to a
nucleic acid affinity spin column (also provided in the kit). Columns were washed
with the recommended wash buffer and DNA was eluted with 200 pL sterile water
into fresh sterile eppendorf tubes.

DNA was quantified by measuring the

absorbance at 260 nm.

Oligonucleotide primers
Genomic DNA from peripheral blood leukocytes served as the template for SDMPCR to detect the factor V Leiden mutation. The sequence for the forward primer
was 5’-TCA ggC Agg AAC AAC ACC AT-3’ [located at nucleotide positions 14831503 within exon 10 of the factor V gene].

For the reverse primer the following

sequence was used 5’-ggT TAC TTC Aag gAC AAA ATA CCT gTA AAg CT-3’
[located between nucleotides 1692-1701 of exon 10 plus an additional 22 bp of
intron 10, surrounding the 5’-end], as previously described by Gandrille et al.
The reverse primer contains 3 base-mismatches (indicated in bold) at the 3’-end
which creates a Hind III restriction site in the allele containing the factor V mutation.
Oligonucleotide primers for the SDM-PCR protocol were synthesised and purified
by Eurogentec (Eurogentec, Abington, UK).

Identification of factor V Leiden by SDM-PCR
Amplification reactions were performed in a final volume of 50 pL consisting of
500 ng genomic DNA template, IX PCR buffer (54 mmol/L Tris-hydrochloric acid
[pH 8.8], 5.4 mmol/L MgCl2, 5.4 pmol/L EDTA, 13.3 mmol/L (NH4)2S04), 300 pmol/L
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of each dNTP, 8% DMSO, 8 mmo!/L p-mercaptoethanol, 0.4 mg/ml BSA, 30 pmoles
of each primer and 2 units Thermus aquaticus (Taq) DNA polymerase (Sigma,
Poole, UK). Amplification was carried out in a PTC-150 minicycler (MJ Research
Inc., Watertown, MA) using the following amplification profile: initial 5 min
denaturation at 94°C, followed by 30 cycles consisting of 1 min denaturation at
94°C, 1 min annealing at 58°C and 1 min extension at 72°C.

Samples were

maintained at 72°C for 7 minutes before holding at 4°C prior to analysis.

For restriction digestion analysis, 20 pL of the PCR product was incubated with 10
units Hind III (Boehringer Manheim, Germany) and 1X buffer (supplied with the
restriction enzyme) for 1.5 hours at 37°C.

Digested products were resolved by

electrophoresis through horizontal 2% low melting point (LMP) agarose gel stained
with 0.5 |ig/mL ethidium

bromide

and

transilluminator (see Fig. 2).
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later viewed

over an

ultra-violet

Results
Direct detection of factor V Leiden using SDM-PCR
The study population was genotyped for factor V Leiden by SDM-PCR.

By

incorporating 3 mismatches in the reverse primer at the 3’-end (see Materials and
Methods), a recognition sequence for the enzyme Hind III is created in the
amplicon only in the presence of the A-allele (i.e. Leiden-mutation).

To

authenticate the SDM-PCR assay, DMA amplicons from a normal individual (Fig.
1a), a heterozygotic Leiden carrier (Fig. 1b) and an individual known to be
homozygotic (Fig. 1c) for the G-^A transition were analysed by direct DNA
sequencing. The diagnostic nucleotide at position 1691 bp is arrowed (Fig. 1). In
Fig. 1b coincident G and A signals arising from both the normal and abnormal
alleles respectively are detected by the sequencing software. This signal conflict is
interpreted as a base-miscall, N. In Fig. la the G1691 nucleotide is present on
both alleles (single black peak) and similarly for the factor V Leiden homozygous
individual (Fig. 1c) A1691 is present (single green peak).

Following PCR of all individual blood samples, the 241 bp amplified DNA fragment
from all individuals is subjected to Hind III digestion and the resulting fragment(s)
resolved in a conventional agarose gel stained with ethidium bromide.
shows a typical set of results.

Figure 2

Individuals who carry a normal factor V gene,

produce a 241 bp DNA fragment which is undigested by Hind III. In comparison,
heterozygous individuals are diagnosed by the presence of a wild type factor V
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allele at 241 bp and the mutated allele at 32 bp (beyond the resolution of the gel
and not evident in Fig. 2) and 209 bp.
The study population was genotyped by SDM-PCR and these data identified the
two heterozygotic thrombotic individuals within the group.

In addition within the

control group one of the participants was diagnosed as heterozygotic also.

No

homozygotic individuals were found in either group.

Modified Coatest® APC resistance assay
Phenotyping was performed by measuring resistance to APC on the forty DVT
patients.

Using the forty normal controls a reference range of 2.3-5.9 was

established, with a mean APC ratio of 4.05 ± 2 SD. The “cut-off” value of 2.3 was
calculated for this test format and samples with a ratio below or equal to the “cut-off”
value were classified as APC resistant or borderline.

The APC ratios were

reproducible with the interassay coefficient of variation for these controls being
6.4% and the mean APC ratio was 3.3. Using the locally established “cut-off” value
of 2.3 the Coatest® APC resistance assay (see Fig. 3) identified 2 individuals (with
APC ratios of < 2.3).

It is interesting to note that one of the latter cases was

identified from among the normal controls, with an APC ratio of 2.0. The thrombotic
patient (Fig. 3), had an APC ratio of 2.3.
several borderline candidates.
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Furthermore this method highlighted

Diagen PCA test
The Diagen PCA kit was also applied to measure APC/PCA ratios in the same
study population. As before, a reference range of 3.3-11.6 was established using
the normal control group with a mean PCA ratio of 7.4 ± 2 SD. Any sample with a
ratio below or equal to the “cut-off” value of 3.3 were classified as APCr or
borderline. Compared to the previous method, patients who were defined as APCr
negative demonstrated PCA ratios that were higher then the corresponding APC
ratios. A value of 5.6% was calculated for the interassay coefficient of variation,
with a mean PCA ratio of 5.2. This assay was highly reproducible.
Following analysis using the Diagen test format, the results in Fig. 4 identified 3
patients with PCA ratios < 3.3. Similar to the Coatest® method, a PCA ratio of 3.1
was obtained for one of the individuals in the control group suggesting APCr. Two
DVT patients were found to be APCr, with PCA ratios of 2.1 and 3.0 respectively.
The diagnostic sensitivity and specificity of both coagulation

assays were

compared (Table 1). Both assays have a similar diagnostic specificity however the
PCA-based assay proved to be more sensitive for phenotypic-based factor V
Leiden determination.
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Discussion
Factor V Leiden associated with activated protein C resistance (APCr) is the
highest prevalent genetic risk factor for venous thrombosis. APCr is found in 2060% of thrombotic cases and 90-95% of APCr patients have the G-^A mutation in
their factor V gene, resulting in an abnormal factor V molecule, factor V Leiden.

®

Many coagulation-based assays have become available to detect APCr and
modifications to the original method increase the sensitivity and specificity of
detection.

As all laboratories now operate within strict financial limits it is

important to maximise the value of diagnostic methods.
clinical and laboratory approaches

In particular combined

will facilitate a laboratory

investigation

programme tailored to each individual patient.

In this study the factor V Leiden status was determined with both the Coatest® and
Diagen APCr assays (phenotypic) and correlated to the individual’s genotype by
SDM-PCR. All of the study population were of Caucasian origin.

Of the 40 DVT

cases submitted to the CIT, all were receiving warfarin therapy.

Seventy-seven

cases in the study population showed normal restriction endonuclease profiles
after SDM-PCR. Three out of 80 (3.75%) carried the factor V Leiden mutation, and
were thus classified as heterozygotic. In the norma! control group the Diagen APCr
ratio was higher than the corresponding Coatest® value (mean 7.4 versus 4.05
respectively).

Two individuals exhibited abnormal ratios in the Coatest® assay.

Interestingly one of these cases was derived from the normal control group (with an
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APCr ratio of 2.0). These results were verified by performing repeat tests.

The

Diagen assay identified three APCr individuals (again the previous control
individual was detected). A second APCr individual was identified by the Diagen
test within the DVT group who was misdiagnosed by the Coatest® assay.

Good correlation exists between the Coatest® and Diagen assay formats, with a
correlation coefficient [r]=1. Nevertheless more borderline ratios were observed
with the Coatest® assay demonstrating a reduced diagnostic sensitivity to factor V
Leiden. While these data shows that the Diagen assay offered better segregation
of affected and non-affected individuals

both assay systems permit confident

prediction of an individuals factor V Leiden status (Table 1). Apart from the single
misdiagnosed subject, concordant results were obtained in 96% of cases studied.
Thus Coatest® and Diagen assays reliably identify ACPr individuals and additional
genotype-based analysis could be rationalised to those cases with discordant
APCr values. When all assay variables are strictly controlled APCr values have the
potential to infer the factor V Leiden genotype,. However, absolute identification of
homozygotic and/or heterozygotic individuals must be confirmed by genotyping. It
should be noted that as factor V Leiden is characterised as an autosomal dominant
disorder, no distinction is made in terms of clinical management.

Although several novel DNA based strategies have been designed to detect the
factor V mutation and other mutations within the coagulation pathway and have the
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overall advantage of direct detection,

by comparison, current coagulation

assays are rapid, inexpensive and easy to perform. Furthermore the latter methods
are more widely available and are not confined to specialised centres, as is the
case for DNA protocols. In the short term, coagulation assays are the method of
choice, facilitating a rapid screen of a patients thrombotic tendency.

However as

the understanding of the complex nature of blood clotting and its control emerges,
and with a concomitant development in molecular detection strategies,
multiplex DNA strategies may in the future provide a more direct diagnosis.
anticipated that molecular methods would
technologies.
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favourably complement

It is

existing
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Sem Cardiothoracic

Table 1: Factor V Leiden specificity and sensitivity data for Coatest® and Diagen
assays

Factor V Genotvoe
Normal

Total Number

Diaanostic
Specificity

Abnormal

77

3

77

1

Sensitivity

fal Coatest® Assay
n APC > 2.3 (N)

n APC < 2.3 (A)

none

O

77

none

100%

75%

100%

100%

fb) Diaaen Assay
n PCA>3.3 (N)

n PCA < 3.3 (A)

none

3

Notes:
n APC/PCA = normalised APC/PCA ratios; N = normal; A = abnormal (factor V
Leiden).
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Figure 1:
Electropherogram of the factor V gene within the exon 10 region showing
nucleotide positions 1690-1699.

Direct sequencing was carried out using the

primers outlined in Materials and Methods

and analysis was performed on an

ABI Prism™ 310 genetic analyser.

(a) Normal factor V allele showing a G at position 1691.

(b) Factor V Leiden heterozygote which shows an ambiguous (N) at position 1691.
This is due to the normal allele having a G at this position and the mutant allele
having

an A, thus the

instrument

software

cannot

identify

both

signals

simultaneously.

(c) Factor V Leiden homozygote which shows an A at position 1691 which creates
a restriction site for Flind III [highlighted in blue].

Notes: Traces for A bases are shown in green, C in blue, G in black and T in red.
The shaded region represents a Flind III restriction site.
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1691

(a)

(b)

(c)
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Figure 2:

Detection of factor V Leiden using site-directed mutagenesis (SDM)-PCR. Initially
specific primers (see Materials and Methods; Gandrille et al.

are used to amplify

the factor V gene within the G-^A mutation site producing an amplicon of 241 bp.
Subsequently each amplicon is subjected to Hind III analysis and digestion of the
amplicon will only take place if the factor V Leiden mutation is present.

Genotypes are given as follows:

Lane 1: PCR amplified fragment for factor V (241 bp) that is undigested.
Lane 2: Factor V normal allele digested with Hind III (241 bp)
Lane 3: Factor V Leiden heterozygote digested with Hind ill (209 and
241 bp)

Note: Lane M represents molecular marker
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M

1

2

3

M

241 bp
209 bp

Figure 3:
Results obtained from normal (left panel) and thrombotic patients (right panel)
measured by the modified Coatest® APCr assay. An APC resistance ratio less than
or equal to 2.3 was considered abnormal (solid line represents this cut-off value).
The latter value was determined from the normal control group.
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Figure 4:
Results obtained from normal controls (left panel) and thrombotic patients (right
panel) measured by the modified Diagent PCA assay. The solid line represents
the “cut-off” value for the assay, 3.3 as determined from the normal control group
(mean ARC -2 SD). An ARC resistance ratio less than or equal to 3.3 was
considered abnormal (solid line represents this cut-off value).
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Summary
Simultaneous fluorescent [F] detection of the factor V Leiden (G1691 A) and the
prothrombin 3’-untranslated region (G20210A) mutations were performed in a
single tube polymerase chain reaction (PCR). Amplification refractory mutation
detection system (ARMS) formed the basis of this assay design.

Fluorescent-

labelled primers incorporated into amplicons during the reaction facilitated
detection directly by GeneScan analysis without further manipulation.

To test

the efficacy of this double [F]-ARMS (dF-ARMS) method, 48 patients with
unexplained thrombotic tendencies were investigated for their factor V Leiden
and prothrombin genotypes.

These results corresponded exactly with data

achieved using the more conventional methods of restriction fragment length
polymorphism (RFLP)-PCR and direct DNA sequencing. Three out of the 48
patients

in

this

group

were

found
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to

be

compound

heterozygotes.

Introduction
Blood coagulation is a complex cascade of reactions between platelets, plasma
factors and the vascular endothelium.

These events culminate in massive

thrombin formation which leads to the formation of an insoluble fibrin clot.
Feedback mechanisms together with other control systems ensure that
inappropriate or excessive activity of the participating enzymes is avoided.

Venous thrombosis is a serious health problem with an incidence of 1 per 1000
annually.

Several genetic and acquired risk factors are known (e.g. surgery,

pregnancy, oral contraceptives among others). Mutations in genes encoding
the blood clotting

pathway components play an

important role in the

predisposition to venous thrombosis. Variant alleles were previously defined for
genes encoding protein C, protein S, antithrombin III and fibrinogen. However
these were recognised in fewer than 5-10% of thrombotic patients (1, 2).

In 1993, activated protein C resistance (APCr) was described (3) and this is now
regarded as the most prevalent coagulation abnormality associated with venous
thrombosis (2-5). It occurs in an estimated 20-65% of patients with a history of
familial

venous

thromboembolism

(5,

6).

Genomic

analysis

clearly

demonstrated that a G to A transition at nucleotide position 1691 in the factor V
gene was responsible for 90-95% of APCr cases (7-9). This mutation produces
a factor Va molecule. Factor V Leiden, with an arginine (R) to glutamine (Q)
amino acid substitution at position 506 in the polypeptide, rendering the protein
partially resistant to inactivation by APC (5, 7). The prevalence of the mutation in
the general population among Western countries varies between 2 and 15%
(1). Recent data however, suggests that this may be influenced by geographic
location and ethnic background (10).
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A genetic variant in the prothrombin gene (factor II) was described in 1996 by
Poort et al. (11) resulting in a G to A transition mutation at nucleotide position
20210 in the 3’-untranslated region (UTR) of this gene. This mutation increases
the concentration of prothrombin in plasma which in turn is associated with an
increased risk of thrombosis (12-15). The prevalence of the mutation in the
prothrombin 3’-UTR is estimated at about 2% in the healthy population and 6%
in unselected consecutive patients with deep vein thrombosis (12, 16).

APCr can be detected by a variety of coagulation based assays (14, 17).
However these vary in specificity and sensitivity and do not permit accurate
evaluation of patients on anticoagulation therapy or those possessing lupus
anticoagulants (5, 18).

For definitive diagnosis of the factor V Leiden and

prothrombin mutations, an accurate DMA based assay would be preferable.
Some of the more recent strategies developed were based on allele specific
amplification (18, 19), whilst others required post-amplification procedures such
as restriction enzyme analysis using Mnll. Hindlll (7, 20-24) to identify these
point mutations.

This report details the development of a double [F]-ARMS PCR assay which
facilitates direct diagnosis using high resolution separation techniques based
on GeneScan technologies.

Fluorescent-labelled oligonucleotide primers are

incorporated into the PCR reaction mixture and the resulting amplicons are
visualised by fluorescence spectroscopy in an ABI Prism^”^ 310 analyser. The
approach described here requires a single tube amplification reaction followed
by direct GeneScan analysis.

Furthermore dF-ARMS can be performed on

whole blood and/or purified genomic DMA as an amplification template.
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Materials and Methods

Blood samples and DNA preparation
Sodium citrate blood samples were collected from 48 consecutive patients
attending

anticoagulation monitoring clinics.

The patients were receiving

anticoagulant therapy because of a previous thrombotic episode associated
with normal proteins C, S and antithrombin III. The white cell content from each
blood sample was separated by centrifugation for 10 min at 2000g at room
temperature and the buffy coat was removed prior to DNA extraction.

Total

genomic DNA v^as recovered from these vyhite cells using a QIAamp Blood Kit
(Qiagen Ltd., West Sussex, UK), according to the manufacturers instructions.
DNA was quantified by measuring the absorbance at 260 nm.
Alternatively, whole blood can be used as a starting template, and is processed
as follows. One microlitre of whole blood is heated to 95°C for 5 min and cooled
to 30°C for 30 sec. This step is repeated three times, after v^hich the PCR
reaction mixture (as outlined below) is added.

Amplification conditions are

outlined below.

Oligonucleotide primers
Each sample was investigated using dye-labelled primers, directed at both the
factor V and prothrombin genes. Genotypes were determined in a single tube
PCR reaction consisting of a common forward primer which was unlabelled,
together with two antisense primers, one of which detected the normal allele
and the second detected the mutated allele.
differentially labelled.

These antisense primers were

All primer characteristics together with other relevant

details are given in Table 1. Oligonucleotide primers for the dF-ARMS protocol
were synthesised and purified by Applied Biosystems, (Applied Biosystems,
Warrington, UK).
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dF-ARMS detection of factor V Leiden and prothrombin mutations
Amplification reactions were performed in a final volume of 50 pi consisting of
500 ng genomic DNA template, 1X PCR buffer (54 mM Tris-HCI, pH 8.8,
5.4 mM MgCl2, 5.4 pM EDTA, 13.3 mM (NH4)2S04), 300 pM of each dNTP,
8% DMSO, 8 mM-mercaptoethanol, 0.4 mg/ml BSA, 15 pmoles of each primer
(Table 1) and 2 U of Tag DNA polymerase (Sigma, Poole, UK). The reaction
mixture was overlaid with mineral oil and amplification was carried out in a
Pharmacia LKB Gene ATAQ Controller (Pharmacia, Uppsala, Sweden), using
the following amplification profile: initial 5 min denaturation at 94°C, followed by
30 cycles consisting of 1 min denaturation at 94°C, 1 min annealing at 62°C and
1 min extension at 72°C.

Samples were maintained at 72°C for 7 minutes

before holding at 4°C prior to analysis.

GeneScan Analysis
TM

For GeneScan analysis 0.5 pi of GeneScan500 TAMRA (N,N,N’,N’tetramethyl-6-carboxyfluorescine) internal size standard (Applied Biosystems,
Warrington, UK) was mixed with 1.0 pi of the PCR reaction and 12 pi HPLC
water. Electrophoresis was performed through a 2.5% GeneScan polymer in
IX GeneScan buffer using a 46 cm capillary, according to the manufacturers
recommendations.

Fluorophore excited emissions were detected in an ABI

Prism^'^ 310 analyser, using virtual filter C. All data peaks were automatically
sized by comparison with the internal lane standard above.

A dedicated

Macintosh ‘PowerMac’ computer (Apple Computer Inc., Foster City, CA) was
used to store data.
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Results
A dF-ARMS protocol was developed to genotype the factor V Leiden and
prothrombin mutations in a single-tube reaction. Two sets of three primers were
included in each reaction mixture and were used to detect normal and abnormal
alleles simultaneously.

Each primer set consisted of an unlabelled forward

primer together with two differentially labelled reverse primers.

Additional

mismatches were included towards the 3’-ends of the reverse primers in order
to increase the specificity of the reaction (Table 1). Primers directed at the factor
V gene were taken from previously published work (25), and those for the
prothrombin gene were specifically designed for this study.

Exon 10 in the

factor V gene and the 3’-UTR region of the prothrombin gene were amplified
from normal individuals together with both homozygotes and heterozygotes for
the R506Q and the G20210A mutations.

Inclusion of dye-labelled primers

permitted the generation of [F]-labelled amplicons during PCR. These products
can

be

detected

directly

(without

post-amplification

modification),

by

genescanning (in an ABI Prism^*^ 310 analyser or similar instrument). Several
annealing temperatures ranging from 58 to 68°C were tested in order to
optimise reaction conditions. Clear discrimination
achieved at an annealing temperature of 62°C.

of all

genotypes was

Figure 1 (a-e) shows the

expected results of the dF-ARMS assay.

When a normal individual was analysed two 6-carboxyfluorescine (FAM)iabelled peaks (blue) were detected corresponding to the normal allelic sizes of
230 and 340 bp for the factor V and prothrombin genes respectively (Fig.1 a).
An additional

hexachloro-6-fluorescine

(HEX)-labelled

detected whenever the abnormal allele was present.

peak

(black)

was

Fig.1 b displays an

individual with a normal prothrombin gene (blue peak only of molecular weight
340 bp) and a heterozygotic factor V locus (black and blue peaks). The reverse
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situation is shown for the individual analysed in Fig.1 c. A subject who was
homozygous (abnormal) for either allele, displays a single HEX-labelled peak at
the corresponding position (Fig.1 d).

Finally a compound heterozygote was

identified in Fig.1 e showing HEX-labelled peaks at both loci. Amplified DMA
fragments were also analysed by restriction fragment length polymorphism
(RFLP)-PCR and direct DMA sequencing (data not shown).

Both methods

confirmed the validity of the dF-ARMS approach.

In order to test the efficacy of dF-ARMS, 48 consecutive patients (with an
unexplained

history of thrombosis but with normal

proteins C, S and

antithrombin III), attending an anticoagulation monitoring clinic, were referred to
the Molecular Diagnostics Unit at CIT for genotyping.

After genomic DMA

extraction all samples were subjected to dF-ARMS. Briefly 44% (21/48) of this
patient group were heterozygous at the factor V locus compared to only 10%
(5/48) carrv'ing the G20210A mutation in the 3’-UTR of the prothrombin gene.
Three out of the 48 patients (6%) were found to be compound heterozygotes.
These results were also confirmed by RFLP-PCR as outlined previously.
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Discussion

Thrombophilia is now recognised as a multigenic disease (12). Comparison of
data obtained from thromboelastography (TEG) measuring the real-time visco
elastic clotting properties of an individual’s blood, and genotype analysis of
factor V and prothrombin clearly demonstrates the necessity for a multiplexbased molecular approach to investigate this complex disease (Maher et al.
submitted). Factor V Leiden and the more recently described prothrombin 3’UTR mutations increase the risk of thromboembolic disease. Much remains to
be uncovered concerning the importance of these and other mutations (e.g.
methylenetetrahydrofolate reductase [MTHFR] C677T mutation (26, 27) leading
to hyperhomocysteinaemia), and how they relate to other conditions on a
broader basis (28). Factor V Leiden is known to interact with acquired factors
(e.g. oral contraceptives, surgery, cancer and others), whilst the prothrombin
mutation has been identified in 18% of selected
thrombophilia (11).

patients with familial

Furthermore, both mutations are now thought to be

associated with coronary artery disease, as indicated by a study on a selected
group of young women presenting with myocardial infarction (12).

Several novel PCR strategies have been described to detect the latter mutations
individually (7, 11, 18-25). The rate-limiting step in many of these protocols is
DNA isolation. Genotyping using both whole blood and purified genomic DNA
templates have been previously reported.

Gomez et al. (21) used a small

volume of whole blood in a multiplex-PCR approach to amplify the regions of
interest from both the factor V and prothrombin genes.

Allelic determination

followed by simultaneous restriction enzyme analysis and careful interpretation
of the agarose gel was required to ensure the assignment of correct
genotype(s).

Ripoll et al. (20) combined detection of both mutations using

purified DNA and Hezard et al. (19), described an allele specific amplification
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(ASA)-PCR method requiring two reaction mixtures (normal and abnormal) for
each template with either purified DNA or whole blood.

In yet another novel

approach, Bowen et al. (27) used a triplex-PCR design, followed by post
amplification heteroduplex analysis, to genotype factor V, prothrombin and
MTHFR alleles. Clearly allele-specific PCR can be used to directly assess the
genotype of significant alleles and is amenable to large-scale screening (28).

After DNA preparation either by purification or using a small volume of whole
blood, the dF-ARMS-PCR method described in this paper facilitates the rapid
and simple evaluation of an individual’s gene profile.

Essentially this method

depends on the correct selection of a complementary allele-specific primer
during the PCR reaction, producing the corresponding dye-labelled amplicon.
Presence or absence of a coloured peak in the GeneScan data is sufficient to
permit direct and unambiguous allelic determination (29). Problems concerning
the interpretation of complex gel patterns are frequently encountered due to
inadequate DNA fragment separation and visualisation.

These difficulties can

be overcome using high-resolution separation techniques, such as those based
on GeneScan

technologies

(28, 29).

No

additional

post-amplification

procedures (such as restriction enzyme digestion or DNA sequencing) are
necessary.

The efficacy of dF-ARMS was tested on 48 patients attending an anticoagulation
clinic and from whom a sample of blood was taken and referred to CIT for factor
V Leiden and prothrombin genotyping. Three out of the 48 patients (6%) were
found to be compound heterozygotes. When compared to more conventional
methods of analysis such as restriction fragment length polymorphism (RFLP)PCR, these results confirm the validity of the dF-ARMS approach.
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Finally for multigenic diseases like thrombophilia,

multiplex-allele specific

amplification methods will play an increasing role in defining an individual’s
genotype. Unambiguous data output will facilitate the rapid implementation of
effective therapeutic measures (30). Ultimately these methods will contribute
towards reducing health economic costs.
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Nucleic

Figure Legends

Figure 1:

Detection of factor V Leiden and prothrombin alleles using dF-ARMS.

Blue

peaks represent 6-FAM-labelled amplicons derived from the normal factor V
and prothrombin genes. Black peaks correspond to HEX-labelled abnormal
mutant amplicons (Table 1). All peaks were sized directly by comparison with
the TAMRA-labelled internal standard (red peaks). Corresponding peak sizes
are indicated in Table

Genotypes are given as follows:

(di) Normal control.
{b)

Factor V Leiden heterozygote and prothrombin normal allele.

(c) Factor V normal allele and prothrombin heterozygous control.
(d) Factor V Leiden horrozygote and prothrombin normal allele.
(e) Compound

heterozygote.

(Factor V

prothrombin alleles).
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Chapter 5
Conclusions and Future Directions

Conclusions

(A)
•

Many coagulation-based assays are available to detect APCr. We examined 40
thrombotic patients and 40 normal individuals for APCr using two common
coagulation assays; an activated partial thromboplastin time (aPPT) assay and
a protein C activator (PCA)-based assay.

•

The results obtained were correlated to the individuals genotype (factor V
Leiden status) using SDM-PCR.

•

These data showed that the Diagen PCA kit detected 3 APCr individuals (one of
these candidates came from the normal group) and SDM-PCR classified all of
these as heterozygotic. The Coatest aPPT assay failed to diagnose one of the
latter individuals proving to be less specific.

•

Coagulation assays have an overall advantage over PCR techniques as they
are rapid, easy to perform and inexpensive. However with the development of
multiplex DMA methods, these may be important in direct diagnosis of an array
of mutations within the coagulation cascade in the future.

(B)
A double fluorescent-ARMS protocol was developed to detect the factor V
Leiden and prothrombin variants in a single tube reaction from whole blood
and/or purified genome DMA.
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Assay design facilitated incorporation of fluorescently-labelled primers into the
amplicons by ARMS which then allowed direct assessment of genotype by
GeneScan analysis.
Presence or absence of a coloured peak in the GeneScan data was sufficient to
permit diagnosis, thus providing a rapid and simple evaluation of an individuals
genotype.
The efficacy of this assay was tested on 48 thrombotic patients. Three were
found to be heterozygous carriers and these results correlated when analysis
was carried out independently using SDM-PCR.

(C)

The prothrombotic tendencies within a cardiac population were analysed using
thromboelastography (TEG) which measures the visco-elastic properties of
blod.

The individuals genotypes were assessed using SDM-PCR protocols to detect
a mutations within components of the coagulation cascade including:
- Factor V Leiden (G1691A)
- Prothrombin variant (G20210A)
- Protein C exon 9 variant (C8403T)
- Protein C TATA variant (A-1533G)
- Antithrombin III variant (G13268T)
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Future directions

Thrombosis is now recognised as a multigenic disease. The recently
discovered defect of the protein C pathway, activated protein C resistance
(APCr) is found in 20-60% of venous thrombosis patients. It is caused by a
mutation in the factor V gene (factor V Leiden) which is present in 90-95% of
APCr cases. Additional research is required to unravel the cause of APCr in the
individuals that are non-carriers of the factor V Leiden variant.
Coagulation-based assays are the method of choice for detecting APCr as they
are rapid, easy to perform and inexpensive. However with the advances in
molecular detection methods, multiplex DMA strategies (i.e. dF-ARMS) may in
the future provide a more direct diagnosis of defects within the coagulation
cascade and may complement existing technologies.
Clinicians still need to decide whether it is beneficial to screen individuals for
APCr before exposure to acquired risk factors such as pregnancy, surgery, oral
contraceptive use, among others.
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Appendix 1
DNA molecular weight size standard

DNA molecular weight marker V was used to allow precise sizing of sample
nucleic acids analysed by agarose gel electrophoresis.

Fragment

Number of base pairs

1

587

2

540

3

504

4

458, 434

5

267

6

234

7

213

8

192, 184

9

124, 123

10

104

11

89, 80

12

64, 57, 51, 18, 11

Appendix 2
GeneScan molecular weight standard

GeneScan™ 500-TAMRA size standard was included in each sample for analysis
using the ABI Prism™ 310 genetic analyzer.

Fragment
number

Size
number (bp)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

50
75
100
139
150
160
200
250
300
340
350
400
450
490
500

Appendix 3
Molecular genetics of factor V Leiden: genetic origins and
modern DNA-based detection strategies
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Appendix 4
Double fluorescent-amplification refractory mutation
detection (dF-ARMS) of the factor V Leiden and prothrombin
mutation
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